研究業績
-
論文
-
337. Super Carbonate Apatite-miR-497a-5p Complex Is a Promising Therapeutic Option against Inflammatory Bowel Disease. Tsujimura N, Ogino T, Hiraki M, Kai T, Yamamoto H, Hirose H, Yokoyama Y, Sekido Y, Hata T, Miyoshi N, Takahashi H, Uemura M, Mizushima T, Doki Y, Eguchi H, Yamamoto H. Pharmaceuticals (Basel). 2023;16(4):618.
336. Tumor-suppressive role of the musculoaponeurotic fibrosarcoma gene in colorectal cancer. Itakura H, Hata T, Okuzaki D, Takeda K, Iso K, Qian Y, Morimoto Y, Adachi T, Hirose H, Yokoyama Y, Ogino T, Miyoshi N, Takahashi H, Uemura M, Mizushima T, Hinoi T, Mori M, Doki Y, Eguchi H, Yamamoto H. iScience. 2023;26(4):106478.
335. Lymph node metastasis in T1 colorectal cancer: Risk factors and prediction model. Fujino S, Miyoshi N, Kitakaze M, Yasui M, Ohue M, Osawa H, Ide Y, Sueda T, Tei M, Takeda T, Danno K, Suzuki Y, Noura S, Ohshima K, Morii E, Takahashi H, Uemura M, Yamamoto H, Murata K, Doki Y, Eguchi H; Clinical Study Group of Osaka University, Colorectal Cancer Treatment Group (CSGOCG). Oncol Lett. 2023;25(5):191. Biomedicines. 2023;11(1):203.
334. The Relationship between LRP6 and Wnt/β-Catenin Pathway in Colorectal and Esophageal Cancer. Shishido A, Miyo M, Oishi K, Nishiyama N, Wu M, Yamamoto H, Kouda S, Wu X, Shibata S, Yokoyama Y, Yamamoto H. Life (Basel). 2023;13(3):615.
333. Simple Detection and Culture of Circulating Tumor Cells from Colorectal Cancer Patients Using Poly(2-Methoxyethyl Acrylate)-Coated Plates. Nomura M, Yokoyama Y, Yoshimura D, Minagawa Y, Yamamoto A, Tanaka Y, Sekiguchi N, Marukawa D, Ichihara M, Itakura H, Matsumoto K, Morimoto Y, Tomihara H, Inoue A, Ogino T, Miyoshi N, Takahashi H, Takahashi H, Uemura M, Kobayashi S, Mizushima T, Anada T, Mori M, Doki Y, Tanaka M, Eguchi H, Yamamoto H. Int J Mol Sci. 2023;24(4):3949
332. Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. Kato T, Kudo T, Kagawa Y, Murata K, Ota H, Noura S, Hasegawa J, Tamagawa H, Ohta K, Ikenaga M, Miyazaki S, Komori T, Uemura M, Nishimura J, Hata T, Matsuda C, Satoh T, Mizushima T, Ohno Y, Yamamoto H, Doki Y, Eguchi H. Sci Rep. 2023;13(1):2331.
331. Single-Cell Analysis of Circulating Tumor Cells from Patients with Colorectal Cancer Captured with a Dielectrophoresis-Based Micropore System. Nomura M, Miyake Y, Inoue A, Yokoyama Y, Noda N, Kouda S, Hata T, Ogino T, Miyoshi N, Takahashi H, Uemura M, Mizushima T, Doki Y, Eguchi H, Yamamoto H. Biomedicines. 2023;11(1):203.
330.KRT13 is upregulated in pancreatic cancer stem-like cells and associated with radioresistance. Takenaka W, Yokoyama Y, Ikehata K, Kouda S, Hirose H, Minami K, Hamada Y, Mori S, Koizumi M, Yamamoto H. J Radiat Res. 2023:rrac091. Online ahead of print. -
329. TRPM8 contributes to liver regeneration via mitochondrial energy metabolism mediated by PGC1α. Lei X, Liu Q, Qin W, Tong Q, Li Z, Xu W, Liu G, Fu J, Zhang J, Kuang T, Shao Y, Liu C, Fang Y, Cao Z, Yan L, Liu Z, Liu S, Yamamoto H, Mori M, Liang X, Xu X.Cell Death Dis. 2022 Dec 16;13(12):1050.
328. Long noncoding RNA 01534 maintains cancer stemness by downregulating endoplasmic reticulum stress response in colorectal cancer. Ichihara M, Takahashi H, Nishida N, Ivan C, Okuzaki D, Yokoyama Y, Ohtsuka M, Miyoshi N, Uemura M, Tanaka S, Calin GA, Mori M, Doki Y, Eguchi H, Yamamoto H. Ann Gastroenterol Surg. 2022;7(3):458-470.
327. Fibroblast Activation Protein and Tertiary Lymphoid Structure in Colorectal Cancer Recurrence. Hayase S, Miyoshi N, Fujino S, Yasui M, Ohue M, Minami S, Kato S, Nagae A, Sekido Y, Hata T, Hamabe A, Ogino T, Takahashi H, Uemura M, Yamamoto H, Doki Y, Eguchi H.Anticancer Res. 2022;42(12):5897-5907.
326. Diagnosis of Depth of Submucosal Invasion in Colorectal Cancer with AI Using Deep Learning. Minami S, Saso K, Miyoshi N, Fujino S, Kato S, Sekido Y, Hata T, Ogino T, Takahashi H, Uemura M, Yamamoto H, Doki Y, Eguchi H. Cancers (Basel). 2022;14(21):5361.
325. Impact of the COVID-19 pandemic on colorectal cancer surgery in Japan: Clinical Study Group of Osaka University-A multicenter retrospective study. Miyo M, Mizushima T, Nishimura J, Hata T, Tei M, Miyake Y, Kagawa Y, Noura S, Ikenaga M, Danno K, Ogawa A, Chinen Y, Hata T, Miyoshi N, Takahashi H, Uemura M, Yamamoto H, Murata K, Doki Y, Eguchi H; Clinical Study Group of Osaka University Colorectal Group. Ann Gastroenterol Surg. 2022:10.1002/ags3.12616.
324. Combined Inflammation and Nutrition Factors Reinforce the Prognostic Prediction for Stage III Colorectal Cancer Patients. Kato S, Miyoshi N, Fujino S, Minami S, Matsuda C, Yasui M, Ohue M, Sekido Y, Hata T, Ogino T, Takahashi H, Uemura M, Yamamoto H, Doki Y, Eguchi H. Anticancer Res. 2022;42(10):4989-4999.
323. PLXND1/SEMA3E Promotes Epithelial-Mesenchymal Transition Partly via the PI3K/AKT-Signaling Pathway and Induces Heterogenity in Colorectal Cancer. Hagihara K, Haraguchi N, Nishimura J, Yasueda A, Fujino S, Ogino T, Takahashi H, Miyoshi N, Uemura M, Matsuda C, Mizushima T, Yamamoto H, Mori M, Doki Y, Eguchi H. Ann Surg Oncol. 2022 Aug 2. Online ahead of print.
322. Transient Receptor Potential Vanilloid-1 (TRPV1) Alleviates Hepatic Fibrosis via TGF-β Signaling. Qian K, Lei X, Liu G, Fang Y, Xie C, Wu X, Liu Q, Liu G, Cao Z, Zhang J, Kuang T, Yan L, Fu J, Du H, Liu Z, Chu Y, Xu G, Yamamoto H, Mori M, Liang XM, Xu X. Dis Markers. 2022;2022:3100943.
321. Micrometastasis in lymph nodes of colorectal cancer. Yamamoto H. Ann Gastroenterol Surg. 2022;6(4):466-473.
320. The Geriatric Nutritional Risk Index as a Prognosis Predictor in Patients With Rectal Cancer Receiving Neoadjuvant Chemotherapy. Minami S, Miyoshi N, Fujino S, Kato S, Sekido Y, Hata T, Ogino T, Takahashi H, Uemura M, Yamamoto H, Doki Y, Eguchi H. Anticancer Res. 2022;42(7):3759-3766.
319. Postoperative pain management after concomitant sacrectomy for locally recurrent rectal cancer. Kitakaze M, Uemura M, Kobayashi Y, Paku M, Miyo M, Takahashi Y, Miyake M, Kato T, Ikeda M, Fujino S, Ogino T, Miyoshi N, Takahashi H, Yamamoto H, Mizushima T, Sekimoto M, Doki Y, Eguchi H.Surg Today. 2022 Jun 4. Online ahead of print.
318. Low G9a expression is a tumor progression factor of colorectal cancer via IL-8 promotion. Ichikawa Y, Takahashi H, Chinen Y, Arita A, Sekido Y, Hata T, Ogino T, Miyoshi N, Uemura M, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Carcinogenesis. 2022;43(8):797-807.
317. The safety and feasibility of laparoscopic redo surgery for recurrent Crohn's disease: A comparative clinical study of over 100 consecutive patients. Ogino T, Sekido Y, Hata T, Miyoshi N, Takahashi H, Uemura M, Yamamoto H, Doki Y, Eguchi H, Mizushima T.Ann Gastroenterol Surg. 2021;6(3):405-411.
316. Development and evaluation of a Japanese prediction model for low anterior resection syndrome after rectal cancer surgery. Paku M, Miyoshi N, Fujino S, Hata T, Ogino T, Takahashi H, Uemura M, Mizushima T, Yamamoto H, Doki Y, Eguchi H.BMC Gastroenterol. 2022;22(1):239.
315. TRPM8 deficiency attenuates liver fibrosis through S100A9-HNF4α signaling. Liu Q, Lei X, Cao Z, Zhang J, Yan L, Fu J, Tong Q, Qin W, Shao Y, Liu C, Liu Z, Wang Z, Chu Y, Xu G, Liu S, Wen X, Yamamoto H, Mori M, Liang XM, Xu X. Cell Biosci. 2022;12(1):58.
314. High postoperative carcinoembryonic antigen as an indicator of high-risk stage II colon cancer. Morimoto Y, Takahashi H, Arita A, Itakura H, Fujii M, Sekido Y, Hata T, Fujino S, Ogino T, Miyoshi N, Uemura M, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Oncol Lett. 2022;23(5):167.
313. A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202). Kato A, Miyoshi N, Ohtsuru T, Sakai D, Hasegawa J, Nakata K, Imasato M, Kato T, Ikenaga M, Kudo T, Tei M, Kagawa Y, Uemura M, Takahashi H, Satoh T, Mori M, Mizushima T, Yamamoto H, Murata K, Doki Y, Eguchi H. Anticancer Res. 2022;42(4):1859-1865.
312. Functional assessment of miR 1291 in colon cancer cells. Wang J, Yokoyama Y, Hirose H, Shimomura Y, Bonkobara S, Itakura H, Kouda S, Morimoto Y, Minami K, Takahashi H, Shibata S, Kobayashi S, Uemura M, Tanaka S, Wu X, Tanaka S, Mori M, Yamamoto H. Int J Oncol. 2022;60(2):13.
311. A stem cell marker KLF5 regulates CCAT1 via three-dimensional genome structure in colorectal cancer cells. Takeda T, Yokoyama Y, Takahashi H, Okuzaki D, Asai K, Itakura H, Miyoshi N, Kobayashi S, Uemura M, Fujita T, Ueno H, Mori M, Doki Y, Fujii H, Eguchi H, Yamamoto H. Br J Cancer. 2022;126(1):109-119.
310. Risk factors for postoperative proximal deep vein thrombosis and pulmonary embolism after laparoscopic colorectal cancer surgery: analysis of a multicenter randomized controlled trial. Yasui M, Ikeda M, Hata T, Okamura S, Miyake Y, Sakisaka H, Takahashi H, Miyoshi N, Uemura M, Mizushima T, Yamamoto H, Murata K, Doki Y, Eguchi H; Clinical Study Group of Osaka University (CSGO), Colorectal Group. Surg Today. 2022;52(6):881-888.
309. Fecal Stream Diversion Changes Intestinal Environment, Modulates Mucosal Barrier, and Attenuates Inflammatory Cells in Crohn's Disease. Watanabe Y, Mizushima T, Okumura R, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Takeda K, Doki Y, Eguchi H. Dig Dis Sci. 2022;67(6):2143-2157. -
308. The efficiency of 18F-FDG-PET/CT in the assessment of tumor response to preoperative chemoradiation therapy for locally recurrent rectal cancer. Uemura M, Ikeda M, Handa R, Danno K, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Eguchi H. BMC Cancer. 2021 Oct 21;21(1):1132.
307. Osteopontin-derived synthetic peptide SVVYGLR upregulates functional regeneration of oral and maxillofacial soft-tissue injury. Tanaka S, Hamada Y, Yokoyama Y, Yamamoto H, Kogo M. Jpn Dent Sci Rev. 2021;57:174-181.
306. Improved In Vivo Delivery of Small RNA Based on the Calcium Phosphate Method. Wu X, Yokoyama Y, Takahashi H, Kouda S, Yamamoto H, Wang J, Morimoto Y, Minami K, Hata T, Shamma A, Inoue A, Ohtsuka M, Shibata S, Kobayashi S, Akai S, Yamamoto H. J Pers Med. 2021;11(11):1160.
305. Circulating MicroRNAs in Gastrointestinal Cancer. Ohtsuka M, Iwamoto K, Naito A, Imasato M, Hyuga S, Nakahara Y, Mikamori M, Furukawa K, Moon J, AsaokaT, Kishi K, Shamma A, Akamatsu H, Mizushima T, Yamamoto H. Cancers (Basel). 2021;13(13):3348.
304. Chk1 suppression leads to a reduction in the enhanced radiation-induced invasive capability on breast cancer cells. Adachi T, Zhao W, Minami K, Yokoyama Y, Okuzaki D, Kondo R, Takahashi Y, Tamari K, Seo Y, Isohashi F, Yamamoto H, Koizumi M, Ogawa K. J Radiat Res. 2021;62(5):764-772.
303. Validation of the conventional Glasgow Prognostic Score and development of the improved Glasgow Prognostic Score in patients with stage 0-III colorectal cancer after curative resection. Ishikawa S, Miyoshi N, Fujino S, Ogino T, Takahashi H, Uemura M, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Ann Gastroenterol Surg. 2021;5(3):345-353.
302. Comprehensive profiling of novel epithelial-mesenchymal transition mediators and their clinical significance in colorectal cancer. Ishikawa S, Nishida N, Fujino S, Ogino T, Takahashi H, Miyoshi N, Uemura M, Satoh T, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Sci Rep. 2021;11(1):11759.
301. Radical lymphadenectomy of a para-aorta lymph node metastasis in colorectal cancer prolongs relapse-free survival. Ichikawa Y, Takahashi H, Fujii M, Hata T, Ogino T, Miyoshi N, Uemura M, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Int J Colorectal Dis. 2021;36(7):1551-1560.
300. Efficacy of positron emission tomography in diagnosis of lateral lymph node metastases in patients with rectal Cancer: a retrospective study. Yukimoto R, Uemura M, Tsuboyama T, Hata T, Fujino S, Ogino T, Miyoshi N, Takahashi H, Hata T, Yamamoto H, Mizushima T, Kida A, Furuyashiki M, Doki Y, Eguchi H. BMC Cancer. 2021;21(1):520.
299. Application of Indocyanine Green Near-Infrared Fluorescence Imaging in Laparoscopic Colectomy for Metachronous Colon Cancer. Dis Colon Rectum. Takahashi H, Ogino T, Miyoshi N, Uemura M, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Dis Colon Rectum. 2021;64(6):e365-e366.
298. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer. Yukimoto R, Nishida N, Hata T, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Satoh T, Hirofumi Y, Mizushima T, Doki Y, Eguchi H. Cancer Sci. 2021;112(7):2884-2894.
297. Impact of the preoperative prognostic nutritional index as a predictor for postoperative complications after resection of locally recurrent rectal cancer. Paku M, Uemura M, Kitakaze M, Fujino S, Ogino T, Miyoshi N, Takahashi H, Yamamoto H, Mizushima T, Doki Y, Eguchi H. BMC Cancer. 2021;21(1):435.
296. ASO Visual Abstract: Application of Local Hyaluronic Acid Injection in Transanal Minimally Invasive Surgery for Anterior Rectal GIST. Takahashi H, Takemasa I, Miyoshi N, Uemura M, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Ann Surg Oncol. 2021;28(7):3775-3776.
295. The synthetic peptide SVVYGLR promotes myogenic cell motility via the TGFβ1/Smad signaling pathway and facilitates skeletal myogenic differentiation in vitro. Hamada Y, Tanaka S, Fujishita Y, Cho JS, Usuki T, Yokoyama Y, Wu X, Mori S, Yamamoto H, Kogo M. Dent Mater J. 2021;40(4):957-963.
294. Targeting cancer stem cells in refractory cancer. Miyoshi N, Haraguchi N, Mizushima T, Ishii H, Yamamoto H, Mori M. Regen Ther. 2021;17:13-19.
293. The synthetic peptide SVVYGLR promotes cell motility of myogenic cells and facilitates differentiation in skeletal muscle regeneration. Tanaka S, Fujishita Y, Kawaguchi N, Usuki T, Yokoyama Y, Wu X, Mori S, Yamamoto H, Kogo M. Dent Mater J. 2021;40(3):766-771.
292. Application of Local Hyaluronic Acid Injection in Transanal Minimally Invasive Surgery for Anterior Rectal GIST. Takahashi H, Takemasa I, Miyoshi N, Uemura M, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Ann Surg Oncol. 2021; 28(7):3774.
291. Polymer-conjugated glucosamine complexed with boric acid shows tumor-selective accumulation and simultaneous inhibition of glycolysis. Islam W, Matsumoto Y, Fang J, Harada A, Niidome T, Ono K, Tsutsuki H, Sawa T, Imamura T, Sakurai K, Fukumitsu N, Yamamoto H, Maeda H. Biomaterials. 2021;269:120631.
290. A case of single-incision laparoscopic surgery for acute appendicitis with left ventricular assist device. Chinen Y, Ogino T, Fujino S, Takahashi H, Miyoshi N, Uemura M, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Asian J Endosc Surg. 2021;14(3):607-610.
289. SIRT3-Mediated SOD2 and PGC-1α Contribute to Chemoresistance in Colorectal Cancer Cells. Paku M, Haraguchi N, Takeda M, Fujino S, Ogino T, Takahashi H, Miyoshi N, Uemura M, Mizushima T, Yamamoto H, Doki Y, Eguchi H. Ann Surg Oncol. 2021;28(8):4720-4732.
288. The meiosis-specific cohesin component stromal antigen 3 promotes cell migration and chemotherapeutic resistance in colorectal cancer. Sasaki M, Miyoshi N, Fujino S, Saso K, Ogino T, Takahashi H, Uemura M, Yamamoto H, Matsuda C, Yasui M, Ohue M, Mizushima T, Doki Y, Eguchi H. Cancer Lett. 2021;497:112-122. - 287. A new fat- dissociation method to detect lymph nodes in colorectal cancer: a prospective randomized study. Fujino S, Miyoshi N, Ohue M, Ito A, Yasui M, Ogino T, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Eguchi H, Matsuura N. Sci Rep. 2020 Nov 19;10(1):20205.
286. A case report of anal canal cancer with pagetoid spread requiring differential diagnosis. Yukimoto R, Fujino S, Miyoshi N, Ogino T, Takahashi H, Uemura M, Tanemura A, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Int J Surg Case Rep. 2020;75:198-202.
285. Synthetic peptide SVVYGLR upregulates cell motility and facilitates oral mucosal wound healing. Tanaka S, Yasuda T, Hamada Y, Kawaguchi N, Fujishita Y, Mori S, Yokoyama Y, Yamamoto H, Kogo M. Peptides. 2020 Dec;134:170405.
284. Direct Delivery of Apatite Nanoparticle-Encapsulated siRNA Targeting TIMP-1 for Intractable Abnormal Scars. Aoki M, Matsumoto NM, Dohi T, Kuwahawa H, Akaishi S, Okubo Y, Ogawa R, Yamamoto H, Takabe K. Mol Ther Nucleic Acids. 2020 Aug 8;22:50-61.
283. Phase I Study of the Administration of Low- dose Perioperative Human Atrial Natriuretic Peptide in Patients With Resectable Colorectal Cancer. Takahashi H, Takeda T, Nishizawa Y, Ogino T, Miyoshi N, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Eguchi H. Anticancer Res. 2020 Sep;40(9):5301-5307.
282. Efficacy of Negative Pressure Wound Therapy Followed by Delayed Primary Closure for Abdominal Wounds in Patients with Lower Gastrointestinal Perforations: Multicenter Prospective Study. Ota H, Danno K, Ohta K, Matsumura T, Komori T, Okamura S, Okano M, Ogawa A, Tamagawa H, Uemura M, Matsuda C, Mizushima T, Yamamoto H, Nezu R, Doki Y, Eguchi H. J Anus Rectum Colon. 2020 Jul 30;4(3):114-121.
281. Long-term outcome of patients with Crohn's disease on home parenteral nutrition. Watanabe Y, Mizushima T, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Doki Y, Eguchi H. Nutrition. 2020 Oct;78:110903.
280. The Geriatric Nutritional Risk Index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery. Sasaki M, Miyoshi N, Fujino S, Ogino T, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y.Sci Rep. 2020 Jul 1;10(1):10744.
279. Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor. Iwamoto K, Takahashi H, Okuzaki D, Osawa H, Ogino T, Miyoshi N, Uemura M, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y, Eguchi H. Br J Cancer. 2020 Jun 29.
278. Human NKp44+ Group 3 Innate Lymphoid Cells Associate with Tumor-Associated Tertiary Lymphoid Structures in Colorectal Cancer. Ikeda A, Ogino T, Kayama H, Okuzaki D, Nishimura J, Fujino S, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Takeda K, Mizushima T, Mori M, Doki Y.Cancer Immunol Res. 2020 Jun;8(6):724-731.
277. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer. Makino S, Takahashi H, Okuzaki D, Miyoshi N, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y. Carcinogenesis. 2020 May 14;41(3):303-312.
276. miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells. Morimoto Y, Mizushima T, Wu X, Okuzaki D, Yokoyama Y, Inoue A, Hata T, Hirose H, Qian Y, Wang J, Miyoshi N, Takahashi H, Haraguchi N, Matsuda C, Doki Y, Mori M, Yamamoto H. Br J Cancer. 2020 Mar;122(7):1037-1049.
275. A rare case of pelvic bronchogenic cyst treated by laparoscopic surgery. Tokuyama S, Takahashi H, Miyoshi N, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y. Asian J Endosc Surg. 2020 Apr;13(2):227-230.
274. Lymph Node Positivity in One-Step Nucleic Acid Amplification is a Prognostic Factor for Postoperative Cancer Recurrence in Patients with Stage II Colorectal Cancer: A Prospective, Multicenter Study. Itabashi M, Yamamoto H, Tomita N, Inomata M, Murata K, Hayashi S, Miyake Y, Igarashi S, Kato T, Noura S, Furuhata T, Ozawa H, Takemasa I, Yasui M, Takeyama H, Okamura S, Ohno Y, Matsuura N. Ann Surg Oncol. 2020 Apr;27(4):1077-1083.
273. Determining the Tumor Suppressive Effects of a New Drug Delivery System Loaded with Iron Oxide Nanoparticles. Ohki A, Yokoyama Y, Yasuda T, Kouda S, Shibata S, Shimomura Y, Wu X, Hamada Y, Mori S, Takeda T, Murase K, Tanaka S, Yamamoto H. Nano Biomedicine. 2020 12(2):43-52.
272. Interstitial cells of Cajal are diminished in critically ill patients: Autopsy cases. Shimizu K, Ogura H, Matsumoto N, Ikeda M, Yamamoto H, Mori M, Morii E, Shimazu T. Nutrition. 2020 Feb;70:110591. - 271. Visceral obesity is a preoperative risk factor for postoperative ileus after surgery for colorectal cancer: Single-institution retrospective analysis. Morimoto Y, Takahashi H, Fujii M, Miyoshi N, Uemura M, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y. Ann Gastroenterol Surg. 2019 Oct 16;3(6):657-666.
270. Clinical significance of invasion distance relative to prognosis in pathological T3 colorectal cancer. Nomura M, Takahashi H, Fujii M, Miyoshi N, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y. Oncol Lett. 2019 Nov;18(5):5614-5620.
269. Efficacy and safety of anticoagulant prophylaxis for prevention of postoperative venous thromboembolism in Japanese patients undergoing laparoscopic colorectal cancer surgery. Hata T, Yasui M, Ikeda M, Miyake M, Ide Y, Okuyama M, Ikenaga M, Kitani K, Morita S, Matsuda C, Mizushima T, Yamamoto H, Murata K, Sekimoto M, Nezu R, Mori M, Doki Y; For Clinical Study Group of Osaka University Colorectal Group (CSGOCG) Investigators. Ann Gastroenterol Surg. 2019 Jul 22;3(5):568-575.
268. E-cadherin-Fc chimera protein matrix enhances cancer stem-like properties and induces mesenchymal features in colon cancer cells. Qian Y, Wu X, Yokoyama Y, Okuzaki D, Taguchi M, Hirose H, Wang J, Hata T, Inoue A, Hiraki M, Ohtsuka M, Takahashi H, Haraguchi N, Mizushima T, Tanaka S, Mori M, Yamamoto H. Cancer Sci. 2019 Nov;110(11):3520-3532
267. Targeting TRPV1 on cellular plasticity regulated by Ovol 2 and Zeb 1 in hepatocellular carcinoma. Xie C, Liu G, Li M, Fang Y, Qian K, Tang Y, Wu X, Lei X, Li X, Liu Q, Liu G, Liu J, Zhang Y, Huang Z, Hu Z, Cao Z, Hu J, Huang S, Zhong D, Huang J, Wu F, Wang J, Mori M, Yamamoto H, Wang J, Xu X. Biomed Pharmacother. 2019 Oct;118:109270.
266. Sphingosine-1-Phosphate Facilitates Skin Wound Healing by Increasing Angiogenesis and Inflammatory Cell Recruitment with Less Scar Formation. Aoki M, Aoki H, Mukhopadhyay P, Tsuge T, Yamamoto H, Matsumoto NM, Toyohara E, Okubo Y, Ogawa R, Takabe K. Int J Mol Sci. 2019 Jul 10;20(14). pii: E3381.
265. Survival outcomes of appendiceal mucinous neoplasms by histological type and stage: Analysis of 266 cases in a multicenter collaborative retrospective clinical study. Sueda T, Murata K, Takeda T, Kagawa Y, Hasegawa J, Komori T, Noura S, Ikeda K, Tsujie M, Ohue M, Ota H, Ikenaga M, Hata T, Matsuda C, Mizushima T, Yamamoto H, Sekimoto M, Nezu R, Mori M, Doki Y. Ann Gastroenterol Surg. 2019 Feb 25;3(3):291-300.
264. Osteopontin-derived synthetic peptide SVVYGLR has potent utility in the functional regeneration of oral and maxillofacial skeletal muscles. Tanaka S, Matsushita Y, Hamada Y, Kawaguchi N, Usuki T, Yokoyama Y, Tsuji T, Yamamoto H, Kogo M. Peptides. 2019 Jun;116:8-15.
263. A rare case of pelvic bronchogenic cyst treated by laparoscopic surgery. Tokuyama S, Takahashi H, Miyoshi N, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y. Asian J Endosc Surg. 2019 Apr 3.
262. Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn's Disease. Watanabe Y, Miyoshi N, Fujino S, Takahashi H, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M, Mizushima T. Dig Dis Sci. 2019 Aug;64(8):2280-2285.
261. Disruption of Endolysosomal RAB5/7 Efficiently Eliminates Colorectal Cancer Stem Cells. Takeda M, Koseki J, Takahashi H, Miyoshi N, Nishida N, Nishimura J, Hata T, Matsuda C, Mizushima T, Yamamoto H, Ishii H, Doki Y, Mori M, Haraguchi N. Cancer Res. 2019 Apr 1;79(7):1426-1437.
260. Factors predictive of high-output ileostomy: a retrospective single-center comparative study. Takeda M, Takahashi H, Haraguchi N, Miyoshi N, Hata T, Yamamoto H, Matsuda C, Mizushima T, Doki Y, Mori M. Surg Today. 2019 Jun;49(6):482-487.
259. Safety of Single-Site Laparoscopic Surgery Requiring Perioperative Heparinization in Colorectal Cancer: Propensity Score-Matched Analysis. Iwamoto K, Takahashi H, Fujii M, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y. Ann Surg Oncol. 2019 Dec;26(13):4390-4396.
258. Safety of laparoscopic colorectal surgery in patients with ventriculoperitoneal shunt. Ichikawa Y, Matsuda C, Mizushima T, Takahashi H, Miyoshi N, Haraguchi N, Hata T, Yamamoto H, Doki Y, Mori M. Asian J Endosc Surg. 2019, 12(3), 264-268. - 257. A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells. Inoue A, Mizushima T, Wu X, Okuzaki D, Kambara N, Ishikawa S, Wang J, Qian Y, Hirose H, Yokoyama Y, Ikeshima R, Hiraki M, Miyoshi N, Takahashi H, Haraguchi N, Hata T, Matsuda C, Doki Y, Mori M,Yamamoto H.Mol Cancer Ther. 2018 May;17(5):977-987.
256. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran Sodium Sulfate-Induced Colitis. Fukata T, Mizushima T, Nishimura J, Okuzaki D, Wu X, Hirose H, Yokoyama Y, Kubota Y, Nagata K, Tsujimura N, Inoue A, Miyoshi N, Haraguchi N, Takahashi H, Hata T, Matsuda C, Kayama H, Takeda K, Doki Y, Mori M, Yamamoto H. Mol Ther Nucleic Acids. 2018 Sep 7;12:658-671.
255. Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment. Tamai K, Mizushima T, Wu X, Inoue A, Ota M, Yokoyama Y, Miyoshi N, Haraguchi N, Takahashi H, Nishimura J, Hata T, Matsuda C, Doki Y, Mori M, Yamamoto H.Mol Cancer Ther. 2018 Jul;17(7):1613-1622.
254. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides. Takahashi H, Misato K, Aoshi T, Yamamoto Y, Kubota Y, Wu X, Kuroda E, Ishii KJ, Yamamoto H, Yoshioka Y.Front Immunol. 2018 Apr 18;9:783.
253. Sox2 is associated with cancer stem-like properties in colorectal cancer. Takeda K, Mizushima T, Yokoyama Y, Hirose H, Wu X, Qian Y, Ikehata K, Miyoshi N, Takahashi H, Haraguchi N, Hata T, Matsuda C, Doki Y, Mori M, Yamamoto H. Sci Rep. 2018 Dec 5;8(1):17639.
252. Mesothelial cells facilitate cancer stem like properties in spheroids of ovarian cancer cells. Shishido A, Mori S, Yokoyama Y, Hamada Y, Minami K, Qian Y, Wang J, Hirose H, Wu X, Kawaguchi N, Nagumo S, Matsuura N, Yamamoto H. Oncol Rep. 2018 Oct;40(4):2105-2114.
251. High Positive End-Expiratory Pressure Renders Spontaneous Effort Noninjurious. Morais CCA, Koyama Y, Yoshida T, Plens GM, Gomes S, Lima CAS, Ramos OPS, Pereira SM, Kawaguchi N, Yamamoto H, Uchiyama A, Borges JB, Vidal Melo MF, Tucci MR, Amato MBP, Kavanagh BP, Costa ELV, Fujino Y.Am J Respir Crit Care Med. 2018 May 15;197(10):1285-1296.
250. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. Nishimura J, Hasegawa J, Kato T, Yoshioka S, Noura S, Kagawa Y, Yasui M, Ikenaga M, Murata K, Hata T, Matsuda C, Mizushima T, Yamamoto H, Doki Y, Mori M; Clinical Study Group of Osaka University (CSGO) Colorectal Group.Cancer Chemother Pharmacol. 2018 Oct;82(4):707-716.
249. A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer. Ikeda M, Sekimoto M, Fukunaga Y, Konishi K, Fujiwara Y, Mizushima T, Takemasa I, Yamamoto H, Doki Y, Mori M. J Anus Rectum Colon. 2018 May 25;1(2):50-55.
248. Overexpression of collagen type III in injured myocardium prevents cardiac systolic dysfunction by changing the balance of collagen distribution. Uchinaka A, Yoshida M, Tanaka K, Hamada Y, Mori S, Maeno Y, Miyagawa S, Sawa Y, Nagata K,Yamamoto H, Kawaguchi N. J Thorac Cardiovasc Surg. 2018 Jul;156(1):217-226.e3.
247. The features of adipose-derived stem cells in patients with inflammatory bowel diseases. Mizushima T, Fukata T, Takeyama H, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C,Yamamoto H, Doki Y, Mori M. Surg Today. 2018 Mar;48(3):352-358.
246. Laparoscopic surgery using a Gigli wire saw for locally recurrent rectal cancer with concomitant intraperitoneal sacrectomy. Uemura M, Ikeda M, Kawai K, Nishimura J, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Mori M. Asian J Endosc Surg. 2018 Feb;11(1):83-86.
245. A novel suction/coagulation integrated probe for achieving better hemostasis: development and clinical use. Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y, Nakajima K. Surg Today. 2018 Jun;48(6):649-655.
244. Clinical benefits of single-incision laparoscopic surgery for postoperative delirium in elderly colon cancer patients. Nishizawa Y, Hata T, Takemasa I, Yamasaki M, Akasaka H, Sugimoto K, Tamai K, Takahashi H, Haraguchi N, Nishimura J, Matsuda C, Mizushima T, Ikenaga M, Yamamoto H, Murata K, Rakugi H, Doki Y, Mori M. Surg Endosc. 2018 Mar;32(3):1434-1440.
243. The features of adipose-derived stem cells in patients with inflammatory bowel diseases. Mizushima T, Fukata T, Takeyama H, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M.Surg Today. 2018 Mar;48(3):352-358.
242. Case of laparoscopic right hemicolectomy for ascending colon cancer after aortic graft replacement and revascularization of the superior mesenteric artery. Hagihara K, Takahashi H, Miyoshi N, Haraguchi N, Hata T, Matsuda C, Mizushima T, Yamamoto H, Doki Y, Mori M. Asian J Endosc Surg. 2018 Aug;11(3):266-269.
241. Colonic ischemia developed after laparoscopic colectomy for rectosigmoid cancer with focal infrarenal aortic stenosis. Ikeda A, Takahashi H, Miyoshi N, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Mori M. Asian J Endosc Surg. 2018 Aug;11(3):270-273.
240. The Severity of Anastomotic Leakage May Negatively Impact the Long-term Prognosis of Colorectal Cancer. Takahashi H, Haraguchi N, Nishimura J, Hata T, Yamamoto H, Matsuda C, Mizushima T, Doki Y, Mori M. Anticancer Res. 2018 Jan;38(1):533-539.
239. Laparoscopic lymph node dissection around the inferior mesenteric artery for left-sided colon and rectal cancer. Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Mori M. Surg Today. 2018 Mar;48(3):359-363.
238. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Miyake Y, Nishimura J, Kato T, Ikeda M, Tsujie M, Hata T, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO).Surg Today. 2018 Jan;48(1):66-72.
237. The efficacy of active drainage for preventing postoperative organ/space surgical site infections in patients with Crohn's disease. Ikeshima R, Mizushima T, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Nakajima K, Yamamoto H, Murata K, Doki Y, Mori M. Surg Today. 2018 Jan;48(1):25-32. - 236. Inspection of Perirectal Lymph Nodes by One-Step Nucleic Acid Amplification Predicts Lateral Lymph Node Metastasis in Advanced Rectal Cancer. Miyake Y, Mizushima T, Hata T, Takahashi H, Hanada H, Shoji H, Nomura M, Haraguchi N, Nishimura J, Matsuda C, Takemasa I, Doki Y, Maeda I, Mori M, Yamamoto H. Ann Surg Oncol. 2017 Dec;24(13):3850-3856.
235. Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer. Hata T, Mokutani Y, Takahashi H, Inoue A, Munakata K, Nagata K, Haraguchi N, Nishimura J, Hata T, Matsuda C, Murata K, Mizushima T, Doki Y, Mori M, Yamamoto H. Int J Oncol. 2017 Feb;50(2):487-496.
234. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R. Cell Rep. 2017, 21(12):3398-3405.
233. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. Nat Commun 9(1):631 2018.
232. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells. Tsubouchi K, Minami K, Hayashi N, Yokoyama Y, Mori S, Yamamoto H, Koizumi M. J Radiat Res. 2017 Nov 1;58(6):816-826.
231. Identification and Characterization of CD107a as a Marker of Low Reactive Oxygen Species in Chemoresistant Cells in Colorectal Cancer. Kitahara T, Haraguchi N, Takahashi H, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Ann Surg Oncol. 2017 Apr;24(4):1110-1119.
230. Non-labeling multiphoton excitation microscopy as a novel diagnostic tool for discriminating normal tissue and colorectal cancer lesions. Matsui T, Mizuno H, Sudo T, Kikuta J, Haraguchi N, Ikeda JI, Mizushima T, Yamamoto H, Morii E, Mori M, Ishii M. Sci Rep. 2017 Jul 31;7(1):6959.
229. The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. Mori S, Hatori N, Kawaguchi N, Hamada Y, Shih TC, Wu CY, Lam KS, Matsuura N, Yamamoto H, Takada YK, Takada Y. Biosci Rep. 2017 Apr 10;37(2): BSR20170173.
228. Evaluation of dermal wound healing activity of synthetic peptide SVVYGLR. Uchinaka A, Kawaguchi N, Ban T, Hamada Y, Mori S, Maeno Y, Sawa Y, Nagata K, Yamamoto H. Biochem Biophys Res Commun. 2017 Sep 23;491(3):714-720.
227. Laminin α2-secreting fibroblasts enhance the therapeutic effect of skeletal myoblast sheets. Uchinaka A, Tasaka K, Mizuno Y, Maeno Y, Ban T, Mori S, Hamada Y, Miyagawa S, Saito A, Sawa Y, Matsuura N, Nagata K, Yamamoto H, Kawaguchi N. Eur J Cardiothorac Surg. 2017 Mar 1;51(3):457-464.
226. Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis. Kawai K, Uemura M, Munakata K, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Murata K, Mizushima T, Yamamoto H, Doki Y, Mori M. Int J Oncol. 2017 Feb;50(2):525-534.
225. Adipose-Derived Stem Cells Ameliorate Experimental Murine Colitis via TSP-1-Dependent Activation of Latent TGF-β. Takeyama H, Mizushima T, Uemura M, Haraguchi N, Nishimura J, Hata T, Matsuda C, Takemasa I, Ikenaga M, Murata K, Yamamoto H, Doki Y, Mori M. Dig Dis Sci. 2017 Aug;62(8):1963-1974.
224. CD103+ Dendritic Cell Function Is Altered in the Colons of Patients with Ulcerative Colitis. Matsuno H, Kayama H, Nishimura J, Sekido Y, Osawa H, Barman S, Ogino T, Takahashi H, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Uchino M, Ikeuchi H, Doki Y, Mori M, Takeda K, Mizushima T. Inflamm Bowel Dis. 2017 Sep;23(9):1524-1534.
223. Low expression of the GOPC is a poor prognostic marker in colorectal cancer. Ohara N, Haraguchi N, Koseki J, Nishizawa Y, Kawai K, Takahashi H, Nishimura J, Hata T, Mizushima T, Yamamoto H, Ishii H, Doki Y, Mori M. Oncol Lett. 2017 Oct;14(4):4483-4490.
222. Laparoscopic surgery for sigmoid colon cancer after multiple operations including urinary diversion with Indiana pouch: A case report. Iwamoto K, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Mori M.Asian J Endosc Surg. 2017 Nov;10(4):420-423.
221. Adherence to an elemental diet for preventing postoperative recurrence of Crohn's disease. Ohara N, Mizushima T, Iijima H, Takahashi H, Hiyama S, Haraguchi N, Inoue T, Nishimura J, Shinzaki S, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M. Surg Today. 2017 Dec;47(12): 1519-1525.
220. Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy. Mizushima T, Fukunaga M, Sueda T, Ikeda M, Kato T, Kim HM, Kudo T, Murata K, Nishimura J, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M.Cancer Chemother Pharmacol. 2017 Jul;80(1): 81-90.
219. Metastasis from a primary hepatic angiosarcoma to the colon: A case report and literature review. Mokutani Y, Hata T, Miyake Y, Kuroda H, Takahashi H, Haraguchi N, Nishimura J, Mizushima T,Yamamoto H, Doki Y, Mori M. Oncol Lett. 2017 Apr;13(4):2765-2769.
218. A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma. Makino S, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Murata K,Yamamoto H, Doki Y, Mori M, Mizushima T.Anticancer Res. 2017 Mar;37(3):1495-1500.
217. High expression of ADAMTS5 is a potent marker for lymphatic invasion and lymph node metastasis in colorectal cancer. Haraguchi N, Ohara N, Koseki J, Takahashi H, Nishimura J, Hata T, Mizushima T, Yamamoto H, Ishii H, Doki Y, Mori M. Mol Clin Oncol. 2017 Jan;6(1):130-134.
216. The single-center experience with the standardization of single-site laparoscopic colectomy for right-sided colon cancer. Takahashi H, Takemasa I, Haraguchi N, Nishimura J, Hata T, Yamamoto H, Matsuda C, Mizushima T, Doki Y, Mori M. Surg Today. 2017 Aug;47(8):966-972.
215. The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer. Nomura M, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Yamamoto H, Murata K, Doki Y, Mori M, Mizushima T.Cancer Chemother Pharmacol. 2017 Dec;80(6):1219-1226.
214. The short-term outcomes of laparoscopic multivisceral resection for locally advanced colorectal cancer: our experience of 39 cases. Miyake Y, Nishimura J, Takahashi H, Haraguchi N, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Surg Today. 2017 May;47(5):575-580.
213. Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents. Hata T, Mizushima T, Osawa H, Takahashi H, Haraguchi N, Nishimura J, Hata T, Takemasa I, Ikenaga M, Nakajima K, Yamamoto H, Murata K, Doki Y, Mori M. Surg Today. 2017 Mar;47(3):320-327.
212. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, Ikenaga M, Ikeda M, Yamamoto H, Satoh T, Hata T, Takemasa I, Mizushima T, Doki Y, Mori M; Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO).Int J Clin Oncol. 2017 Feb;22(1):88-95.
211. Comparison of bleeding risks related to venous thromboembolism prophylaxis in laparoscopic vs open colorectal cancer surgery: a multicenter study in Japanese patients. Yasui M, Ikeda M, Miyake M, Ide Y, Okuyama M, Shingai T, Kitani K, Ikenaga M, Hasegawa J, Akamatsu H, Murata K, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M; Clinical Study Group of Osaka University (CSGO), Colorectal Group.Am J Surg. 2017 Jan;213(1):43-49.
210. Safety and efficacy of an "enhanced recovery after surgery" protocol for patients undergoing colon cancer surgery: a multi-institutional controlled study. Ota H, Ikenaga M, Hasegawa J, Murata K, Miyake Y, Mizushima T, Hata T, Takemasa I, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Surg Today. 2017 Jun;47(6):668-675.
209. Regeneration of peritoneal mesothelial cells after placement of hyaluronate carboxymethyl-cellulose (Seprafilm®). Osawa H, Nishimura J, Hiraki M, Takahashi H, Haraguchi N, Hata T, Ikenaga M, Murata K, Yamamoto H, Mizushima T, Doki Y, Mori M. Surg Today. 2017 Jan;47(1):130-136.
208. X-ray and Carbon Ion Beam Irradiation Inhibited Angiogenesis via Integrin Up-regulation. Minami K, Hamada Y, Kawaguchi N, Mori S, Yokoyama Y, Oki Y, Adachi T, Kondo R, Shishido A, Matsushita Y, Usuki T, Manabe M, Koizumi M, Ogawa K, Yamamoto H. Nano Biomedicine. 2017 9(2) 94 – 104.
207. The changes in metastatic potential of radioresistant cancer cell line generated by frequent X-ray. Minami K, Hamada Y, Kawaguchi N, Mori S, Nakatani K, Tsubouchi K, Hayashi N, Uchinaka A, Yokoyama Y, Yamamoto H, Koizumi M. Osaka University Health Economics Management discussion papers. 2017 E001. - 206. Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. Yamamoto H, Murata K, Fukunaga M, Ohnishi T, Noura S, Miyake Y, Kato T, Ohtsuka M, Nakamura Y, Takemasa I, Mizushima T, Ikeda M, Ohue M, Sekimoto M, Nezu R, Matsuura N, Monden M, Doki Y, Mori M. Clin Cancer Res. 2016 Jul 1;22(13):3201-8.
205. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. Cancer Res. 2016;76(21) 6320-30.
204. BET Bromodomain Inhibition Promotes Anti-Tumor Immunity by Suppressing PD-L1 expression. Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R. Cell Rep. 2016; 16(11) 2829-37.
203. OSNA-Assisted Molecular Staging in Colorectal Cancer: A Prospective Multicenter Trial in Japan. Yamamoto H, Tomita N, Inomata M, Furuhata T, Miyake Y, Noura S, Kato T, Murata K, Hayashi S, Igarashi S, Itabashi M, Kameoka S, Matsuura N. Ann Surg Oncol. 2016 Feb;23(2):391-6.
202. Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity. Munakata K, Uemura M, Tanaka S, Kawai K, Kitahara T, Miyo M, Kano Y, Nishikawa S, Fukusumi T, Takahashi Y, Hata T, Nishimura J, Takemasa I, Mizushima T, Ikenaga M, Kato T, Murata K, Carethers JM, Yamamoto H, Doki Y, Mori M. Clin Cancer Res. 2016 Nov 1;22(21):5277-5286.
201. MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics. Yamamoto H, Mori M.Adv Exp Med Biol. 2016;937:239-47.
200. Down-Regulation of microRNA-132 is Associated with Poor Prognosis of Colorectal Cancer. Mokutani Y, Uemura M, Munakata K, Okuzaki D, Haraguchi N, Takahashi H, Nishimura J, Hata T, Murata K, Takemasa I, Mizushima T, Doki Y, Mori M, Yamamoto H. Ann Surg Oncol. 2016 Dec;23(Suppl 5):599-608.
199. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S. Nat Med. 2016 Jun;22(6):679-84.
198. Characteristics of carbonic anhydrase 9 expressing cells in human intestinal crypt base. Takahashi H, Suzuki Y, Nishimura J, Haraguchi N, Ohtsuka M, Miyazaki S, Uemura M, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Int J Oncol. 2016 Jan;48(1):115-22.
197. Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. Uchi R, Takahashi Y, Niida A, Shimamura T, Hirata H, Sugimachi K, Sawada G, Iwaya T, Kurashige J, Shinden Y, Iguchi T, Eguchi H, Chiba K, Shiraishi Y, Nagae G, Yoshida K, Nagata Y, Haeno H,Yamamoto H, Ishii H, Doki Y, Iinuma H, Sasaki S, Nagayama S, Yamada K, Yachida S, Kato M, Shibata T, Oki E, Saeki H, Shirabe K, Oda Y, Maehara Y, Komune S, Mori M, Suzuki Y, Yamamoto K, Aburatani H, Ogawa S, Miyano S, Mimori K. PLoS Genet. 2016 Feb 18;12(2):e1005778.
196. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. Sueda T, Sakai D, Kawamoto K, Konno M, Nishida N, Koseki J, Colvin H, Takahashi H, Haraguchi N, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Satoh T, Doki Y, Mori M, Ishii H.Sci Rep. 2016 Jan 11;6:18949.
195 Long-term outcome of adrenalectomy for metastasis resulting from colorectal cancer with other metastatic sites: A report of 3 cases. Uemura M, Kim HM, Ikeda M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Oncol Lett. 2016 Sep;12(3):1649-1654.
194. Detection of Anorectal Cancer among Patients with Crohn's Disease Undergoing Surveillance with Various Biopsy Methods. Matsuno H, Mizushima T, Nezu R, Nakajima K, Takahashi H, Haraguchi N, Nishimura J, Hata T,Yamamoto H, Doki Y, Mori M. Digestion. 2016;94(1):24-9.
193. Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer. Hata T, Kudo T, Sakai D, Takahashi H, Haraguchi N, Nishimura J, Hata T, Mizushima T, Yamamoto H, Doki Y, Mori M, Satoh T. Cancer Chemother Pharmacol. 2016 Aug;78(2):389-96.
192. Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer. Osawa H, Takahashi H, Nishimura J, Ohta K, Haraguchi N, Hata T, Yamamoto H, Mizushima T, Takemasa I, Doki Y, Mori M. Br J Cancer. 2016 May 24;114(11):1251-60.
191. (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer. Nishimura J, Hasegawa J, Ogawa Y, Miwa H, Uemura M, Haraguchi N, Hata T, Yamamoto H, Takemasa I, Mizushima T, Nezu R, Doki Y, Mori M.Surg Today. 2016 Oct;46(10):1152-8.
190. A clinical trial of autologous adipose-derived regenerative cell transplantation for a postoperative enterocutaneous fistula. Mizushima T, Takahashi H, Takeyama H, Naito A, Haraguchi N, Uemura M, Nishimura J, Hata T, Takemasa I, Yamamoto H, Doki Y, Mori M. Surg Today. 2016 Jul;46(7):835-42.
189. Single-incision laparoscopic surgery for stricturing and penetrating Crohn's disease. Mizushima T, Nakajima K, Takeyama H, Naito A, Osawa H, Uemura M, Nishimura J, Hata T, Takemasa I, Yamamoto H, Doki Y, Mori M. Surg Today. 2016 Feb;46(2):203-8.
- 188. Innovative delivery of siRNA to solid tumors by super carbonate apatite. Wu X, Yamamoto H, Nakanishi H, Yamamoto Y, Inoue A, Tei M, Hirose H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Hossain S, Akaike T, Matsuura N, Doki Y, Mori M. PLoS One. 2015 Mar 4;10(3):e0116022.
187. Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M, Nishida N, Uemura M, Hata T, Takemasa I, Mizushima T, Soh JW, Doki Y, Mori M, Yamamoto H. Mol Ther Nucleic Acids. 2015 Mar 10;4(3):e231.
186. A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects. Yamamoto H, Wu X, Nakanishi H, Yamamoto Y, Uemura M, Hata T, Nishimura J, Takemasa I, Mizushima T, Sasaki J, Imazato S, Matsuura N, Doki Y, Mori M. Sci Rep. 2015 Jan 13;5:7742.
185. RFPL4A increases the G1 population and decreases sensitivity to chemotherapy in human colorectal cancer cells. Naito A, Yamamoto H, Kagawa Y, Naito Y, Okuzaki D, Otani K, Iwamoto Y, Maeda S, Kikuta J, Nishikawa K, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Ishii H, Doki Y, Mori M, Ishii M. J Biol Chem. 2015 Mar 6;290(10):6326-37.
184. Significance of Polypyrimidine Tract-Binding Protein 1 Expression in Colorectal Cancer. Takahashi H, Nishimura J, Kagawa Y, Kano Y, Takahashi Y, Wu X, Hiraki M, Hamabe A, Konno M, Haraguchi N, Takemasa I, Mizushima T, Ishii M, Mimori K, Ishii H, Doki Y, Mori M, Yamamoto H. Mol Cancer Ther. 2015 Jul;14(7):1705-16.
183. A Cancer Reprogramming Method Using MicroRNAs as a Novel Therapeutic Approach against Colon Cancer: Research for Reprogramming of Cancer Cells by MicroRNAs. Miyazaki S, Yamamoto H, Miyoshi N, Wu X, Ogawa H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Konno M, Doki Y, Mori M, Ishii H. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1394-401.
182. MicroRNAs Induce Epigenetic Reprogramming and Suppress Malignant Phenotypes of Human Colon Cancer Cells. Ogawa H, Wu X, Kawamoto K, Nishida N, Konno M, Koseki J, Matsui H, Noguchi K, Gotoh N,Yamamoto T, Miyata K, Nishiyama N, Nagano H, Yamamoto H, Obika S, Kataoka K, Doki Y, Mori M, Ishii H. PLoS One. 2015 May 13;10(5):e0127119.
181. MicroRNA-29b is a Novel Prognostic Marker in Colorectal Cancer. Inoue A, Yamamoto H, Uemura M, Nishimura J, Hata T, Takemasa I, Ikenaga M, Ikeda M, Murata K, Mizushima T, Doki Y, Mori M. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1410-8.
180. Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer. Nonaka R, Miyake Y, Hata T, Kagawa Y, Kato T, Osawa H, Nishimura J, Ikenaga M, Murata K, Uemura M, Okuzaki D, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Int J Oncol. 2015 Sep;47(3):1097-102.
179. A novel single-stapling technique for colorectal anastomosis: a pre-ligation single-stapling technique (L-SST) in a porcine model. Takeyama H, Yamamoto H, Hata T, Takahashi Y, Ohtsuka M, Nonaka R, Inoue A, Naito A, Matsumura T, Uemura M, Nishimura J, Takemasa I, Mizushima T, Doki Y, Mori M. Surg Endosc. 2015 Aug;29(8):2371-6.
178. Effect of particle beam radiotherapy on locally recurrent rectal cancer: Three case reports. Mokutani Y, Yamamoto H, Uemura M, Haraguchi N, Takahashi H, Nishimura J, Hata T, Takemasa I, Mizushima T, Doki Y, Mori M. Mol Clin Oncol. 2015 Jul;3(4):765-769.
177. SVVYGLR motif of the thrombin-cleaved N-terminal osteopontin fragment enhances the synthesis of collagen type III in myocardial fibrosis. Uchinaka A, Hamada Y, Mori S, Miyagawa S, Saito A, Sawa Y, Matsuura N, Yamamoto H, Kawaguchi N. Mol Cell Biochem. 2015 Oct;408(1-2):191-203.
176. C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis. Miyake T, Ito T, Yanai A, Inoue N, Miyagawa Y, Murase K, Imamura M, Ichii S, Takatsuka Y, Nishizaki T, Hirota S, Ohtsuka M, Yamamoto H, Noguchi S, Miyoshi Y. Breast Cancer. 2015; 22(4) 366-373.
175. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Eur J Cancer. 2015 Jul;51(10):1274-82.
174. Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein. Takeyama H, Mizushima T, Iijima H, Shinichiro S, Uemura M, Nishimura J, Hata T, Takemasa I,Yamamoto H, Doki Y, Mori M. Dig Dis Sci. 2015 Nov;60(11):3418-23.
173. Single-site laparoscopic colectomy for rectosigmoid cancer with middle aortic syndrome: report of a case. Tamai K, Takemasa I, Uemura M, Nishimura J, Hata T, Higashihara H, Osuga K, Mizushima T,Yamamoto H, Doki Y, Mori M. Surg Case Rep. 2015;1(1):53.
172. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. Mizushima T, Tamagawa H, Matsuda C, Murata K, Fukunaga M, Ota H, Hasegawa J, Tsujie M, Fukuzaki T, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Oncology. 2015;89(3):152-8.
171. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer. Matsuda C, Uemura M, Nakata K, Shingai T, Nishimura J, Hata T, Ikenaga M, Takemasa I, Mizushima T, Kato T, Ikeda M, Ohue M, Murata K, Hasegawa J, Satoh T, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. BMC Cancer. 2015 Jun 3;15:452.
170. Overexpression of Transcription Termination Factor 1 is Associated with a Poor Prognosis in Patients with Colorectal Cancer. Ueda M, Iguchi T, Nambara S, Saito T, Komatsu H, Sakimura S, Hirata H, Uchi R, Takano Y, Shinden Y, Eguchi H, Masuda T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1490-8.
169. Preoperative Chemoradiation Followed by Extensive Pelvic Surgery Improved the Outcome of Posterior Invasive Locally Recurrent Rectal Cancer without Deteriorating Surgical Morbidities: A Retrospective, Single-Institution Analysis. Ogawa H, Uemura M, Nishimura J, Hata T, Ikenaga M, Takemasa I, Mizushima T, Ikeda M, Sekimoto M, Yamamoto H, Doki Y, Mori M. Ann Surg Oncol. 2015 Dec;22(13):4325-34.
168. Surgical management of perforated gastrointestinal posttransplantation lymphoproliferative disorder after heart transplantation. Osawa H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Int Surg. 2015 Feb;100(2):358-64.
167. Single-incision laparoscopic rectopexy (Wells) with simultaneous sigmoidectomy in a case of complete rectal prolapse and a sigmoid tumor: report of a case. Miyo M, Takemasa I, Mokutani Y, Uemura M, Nishimura J, Hata T, Mizushima T, Yamamoto H, Doki Y, Mori M. Surg Today. 2015 Jun;45(6):793-8.
166. Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer. Takeyama H, Yamamoto H, Yamashita S, Wu X, Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata K, Ohue M, Kato T, Takemasa I, Mizushima T, Ishii H, Mimori K, Doki Y, Mori M. Mol Cancer Ther. 2014 Apr;13(4):976-85.
165. Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Yokoyama Y, Matsumoto A, Hieda M, Shinchi Y, Ogihara E, Hamada M, Nishioka Y, Kimura H, Yoshidome K, Tsujimoto M, Matsuura N. Breast Cancer Res. 2014;16(3) R66.
164. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, Shaker MN, Hamakawa T, Takahashi T, Takiguchi S, Mori M, Doki Y. Ann Surg Oncol Suppl. 2014; 4S584-90.
163. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K, Nishida N, Koseki J, Mimori K, Gotoh N, Yamamoto H, Doki Y, Mori M, Ishii H. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15526-31.
162. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, Furuta K, Nakajima T, Hayashi H, Sugisaki H, Higashimoto H, Kato T, Takeshita F, Ochiya T. Nat Commun. 2014 Apr 7;5:3591.
161. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Nonaka R, Nishimura J, Kagawa Y, Osawa H, Hasegawa J, Murata K, Okamura S, Ota H, Uemura M, Hata T, Takemasa I, Mizushima T, Okuzaki D, Yamamoto H, Doki Y, Mori M. Oncol Rep. 2014 Dec;32(6):2354-8.
160. Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Hamabe A, Yamamoto H, Konno M, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Nishida N, Kawamoto K, Koseki J, Doki Y, Mori M, Ishii H. Cancer Sci. 2014 Sep;105(9):1100-8.
159. Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma. Wada H, Yamamoto H, Kim C, Uemura M, Akita H, Tomimaru Y, Hama N, Kawamoto K, Kobayashi S, Eguchi H, Umeshita K, Doki Y, Mori M, Nagano H. Int J Oncol. 2014 Sep;45(3):1051-8.
158. SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance. Munakata K, Uemura M, Takemasa I, Ozaki M, Konno M, Nishimura J, Hata T, Mizushima T, Haraguchi N, Noura S, Ikenaga M, Okamura S, Fukunaga M, Murata K, Yamamoto H, Doki Y, Mori M. Int J Oncol. 2014 May;44(5):1521-8.
157. A novel endoscopic fluorescent clip visible with near-infrared imaging during laparoscopic surgery in a porcine model. Takeyama H, Hata T, Nishimura J, Nonaka R, Uemura M, Haraguchi N, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Surg Endosc. 2014 Jun;28(6):1984-90.
156. Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases. Hiraki M, Nishimura J, Ohtsuka M, Shiomi H, Uemura M, Haraguchi N, Hata T, Hayashi T, Takemasa I, Mizushima T, Isohashi F, Yoshioka Y, Ogawa K, Doki Y, Mori M, Yamamoto H. Oncol Rep. 2014 Feb;31(2):795-9.
155. Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer. Naito A, Mizushima T, Takeyama H, Sakai D, Uemura M, Kudo T, Nishimura J, Shinzaki S, Hata T, Sato T, Takemasa I, Nakajima K, Iijima H, Yamamoto H, Doki Y, Mori M. Hepatogastroenterology. 2014 Jun;61(132):942-6.
154. Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. Sueda T, Kudo T, Sakai D, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Ezoe S, Matsumoto K, Doki Y, Mori M, Satoh T. Cancer Chemother Pharmacol. 2014 Dec;74(6):1321-4.
153. MACC1 expression levels as a novel prognostic marker for colorectal cancer. Yamamoto H, Miyoshi N, Mimori K, Hitora T, Tokuoka M, Fujino S, Ellis HL, Ishii H, Noura S, Ohue M, Yano M, Doki Y, Mori M. Oncol Lett. 2014 Nov;8(5):2305-2309.
152. ANXA9 gene expression in colorectal cancer: A novel marker for prognosis. Miyoshi N, Yamamoto H, Mimori K, Yamashita S, Miyazaki S, Nakagawa S, Ishii H, Noura S, Ohue M, Yano M, Doki Y, Mori M. Oncol Lett. 2014 Nov;8(5):2313-2317.
151. Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Ueda M, Takahashi Y, Shinden Y, Sakimura S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Anticancer Res. 2014 Oct;34(10):5357-62.
150. Short-term outcomes of simultaneous laparoscopic colectomy and hepatectomy for primary colorectal cancer with synchronous liver metastases. Inoue A, Uemura M, Yamamoto H, Hiraki M, Naito A, Ogino T, Nonaka R, Nishimura J, Wada H, Hata T, Takemasa I, Eguchi H, Mizushima T, Nagano H, Doki Y, Mori M. Int Surg. 2014 Jul-Aug;99(4):338-43.
149. Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer. Matsumura T, Sugimachi K, Takahashi Y, Uchi R, Sawada G, Ueda M, Hirata H, Sakimura S, Ueo H, Takano Y, Kurashige J, Shinden Y, Eguchi H, Sudo T, Yamamoto H, Doki Y, Mori M, Mimori K. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S743-9.
148. Evaluation of invasiveness in single-site laparoscopic colectomy, using "the PainVision™ system" for quantitative analysis of pain sensation. Hiraki M, Takemasa I, Uemura M, Haraguchi N, Nishimura J, Hata T, Mizushima T, Yamamoto H, Doki Y, Mori M. Surg Endosc. 2014 Nov;28(11):3216-23.
147. Successful treatment of rectal cancer with perineal invasion: Three case reports. Kitahara T, Uemura M, Haraguchi N, Nishimura J, Shingai T, Hata T, Takemasa I, Mizushima T, Doki Y, Mori M, Yamamoto H. Mol Clin Oncol. 2014 Jul;2(4):497-500.
146. Short-term clinical outcomes of postoperative intrapelvic bleeding after extended pelvic surgery: a single institute experience. Ogawa H, Mizushima T, Takemasa I, Yamamoto H, Doki Y, Mori M. Anticancer Res. 2014 Jun;34(6):3169-76.
145. Survival benefit of oral tegafur/uracil and leucovorin as a first line therapy for elderly patients with advanced or metastatic colorectal cancer. Murata K, Yamamoto H, Fukunaga M, Kato T, Ohnishi T, Uemura Y, Ohta H, Kimura F, Ohue M, Nezu R, Sekimoto M, Ikeda M, Mizushimaz T, Doki Y, Mori M; Clinical Study Group of Osaka University (CSGO) Colorectal Group. Hepatogastroenterology. 2014 Jan-Feb;61(129):94-8.
144. Human colorectal CD24+ cancer stem cells are susceptible to epithelial-mesenchymal transition. Okano M, Konno M, Kano Y, Kim H, Kawamoto K, Ohkuma M, Haraguchi N, Yokobori T, Mimori K, Yamamoto H, Sekimoto M, Doki Y, Mori M, Ishii H. Int J Oncol. 2014 Aug;45(2):575-80.
143. Laparoscopic surgery for stage IV colorectal cancer. Ohta K, Takemasa I, Uemura M, Nishimura J, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M. Surg Laparosc Endosc Percutan Tech. 2014 Apr;24(2):153-7.
142. The effects of chemotherapy on primary small bowel cancer: A retrospective multicenter observational study in Japan. Mizushima T, Tamagawa H, Mishima H, Ikeda K, Fujita S, Akamatsu H, Ikenaga M, Onishi T, Fukunaga M, Fukuzaki T, Hasegawa J, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M.Mol Clin Oncol. 2013 Sep;1(5):820-824.
141. Preoperative evaluation of venous anatomy in laparoscopic complete mesocolic excision for right colon cancer. Ogino T, Takemasa I, Horitsugi G, Furuyashiki M, Ohta K, Uemura M, Nishimura J, Hata T, Mizushima T, Yamamoto H, Doki Y, Mori M. Ann Surg Oncol. 2014 Jun;21 Suppl 3:S429-35.
140. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim HM, Takemoto H, Tamagawa H, Noura S, Fujii M, Fujie Y, Kato T, Miwa H, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Cancer Chemother Pharmacol. 2014 May;73(5):1079-87.
139. Feasibility of single-port laparoscopic surgery for sigmoid colon and rectal cancers and preoperative assessment of operative difficulty. Hamabe A, Takemasa I, Uemura M, Nishimura J, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M.J Gastrointest Surg. 2014 May;18(5):977-85.
138. Feasibility of single-site laparoscopic colectomy with complete mesocolic excision for colon cancer: a prospective case-control comparison. Takemasa I, Uemura M, Nishimura J, Mizushima T, Yamamoto H, Ikeda M, Sekimoto M, Doki Y, Mori M. Surg Endosc. 2014 Apr;28(4):1110-8.
137. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. Takahashi Y, Iwaya T, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Ann Surg Oncol. 2014 Jan;21(1):205-12. - 136. Emerging methods for preparing iPS cells. Miyazaki S, Yamamoto H, Miyoshi N, Takahashi H, Suzuki Y, Haraguchi N, Ishii H, Doki Y, Mori M. Jpn J Clin Oncol. 2012 Sep;42(9):773-9.
135. Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Yokoyama Y, Hieda M, Nishioka Y, Matsumoto A, Higashi S, Kimura H, Yamamoto H, Mori M, Matsuura S, Matsuura N.Cancer Sci. 2013 Jul;104(7):889-95.
134. C4.4A expression is associated with a poor prognosis of esophageal squamous cell carcinoma. Ohtsuka M, Yamamoto H, Masuzawa T, Takahashi H, Uemura M, Haraguchi N, Nishimura J, Hata T, Yamasaki M, Miyata H, Takemasa I, Mizushima T, Takiguchi S, Doki Y, Mori M. Ann Surg Oncol. 2013 Aug;20(8):2699-705.
133. Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo. Suzuki R, Yamamoto H, Ngan CY, Ohtsuka M, Kitani K, Uemura M, Nishimura J, Takemasa I, Mizushima T, Sekimoto M, Minamoto T, Doki Y, Mori M. Int J Oncol. 2013 Nov;43(5):1447-55.
132. Concurrent expression of C4.4A and Tenascin-C in tumor cells relates to poor prognosis of esophageal squamous cell carcinoma. Ohtsuka M, Yamamoto H, Oshiro R, Takahashi H, Masuzawa T, Uemura M, Haraguchi N, Nishimura J, Hata T, Yamasaki M, Takemasa I, Miyata H, Mizushima T, Takiguchi S, Doki Y, Mori M. Int J Oncol. 2013 Aug;43(2):439-46.
131. Distinct expression of C4.4A in colorectal cancer detected by different antibodies. Yamamoto H, Oshiro R, Ohtsuka M, Uemura M, Haraguchi N, Nishimura J, Takemasa I, Mizushima T, Doki Y, Mori M. Int J Oncol. 2013 Jan;42(1):197-201.
130. SSEA-3 as a novel amplifying cancer cell surface marker in colorectal cancers. Suzuki Y, Haraguchi N, Takahashi H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Ishii H, Doki Y, Mori M, Yamamoto H. Int J Oncol. 2013 Jan;42(1):161-7.
129. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease. Ogino T, Nishimura J, Barman S, Kayama H, Uematsu S, Okuzaki D, Osawa H, Haraguchi N, Uemura M, Hata T, Takemasa I, Mizushima T, Yamamoto H, Takeda K, Doki Y, Mori M. Gastroenterology. 2013 Dec;145(6):1380-91.e1.
128. Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors. Yamamoto H, Oshiro R, Nishimura J, Uemura M, Haraguchi N, Hata T, Takemasa I, Mizushima T, Sekimoto M, Doki Y, Mori M. Oncol Rep. 2013 May;29(5):1751-5.
127. Cell cycle-dependent Rho GTPase activity dynamically regulates cancer cell motility and invasion in vivo. Kagawa Y, Matsumoto S, Kamioka Y, Mimori K, Naito Y, Ishii T, Okuzaki D, Nishida N, Maeda S, Naito A, Kikuta J, Nishikawa K, Nishimura J, Haraguchi N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Ishii H, Doki Y, Matsuda M, Kikuchi A, Mori M, Ishii M. PLoS One. 2013 Dec 30;8(12):e83629.
126. Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer. Yamamoto H, Tei M, Uemura M, Takemasa I, Uemura Y, Murata K, Fukunaga M, Ohue M, Ohnishi T, Ikeda K, Kato T, Okamura S, Ikenaga M, Haraguchi N, Nishimura J, Mizushima T, Mimori K, Doki Y, Mori M. Int J Oncol. 2013 Feb;42(2):549-55.
125. Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: effect on growth retardation of established colon tumor. Hossain S, Yamamoto H, Chowdhury EH, Wu X, Hirose H, Haque A, Doki Y, Mori M, Akaike T. PLoS One. 2013 Apr 16;8(4):e60428.
124. A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer. Mizushima T, Ide Y, Murata K, Ohashi I, Yasumasa K, Fukunaga M, Takemoto H, Tamagawa H, Hasegawa J, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Oncology. 2013;85(6):317-22.
123. Metachronous, colitis-associated rectal cancer that developed after sporadic adenocarcinoma in an adenoma in a patient with longstanding Crohn's disease: a case report. Takeyama H, Mizushima T, Nakajima K, Uemura M, Haraguchi N, Nishimura J, Hata T, Takemasa I, Yamamoto H, Doki Y, Mori M. World J Surg Oncol. 2013 Nov 19;11:295.
122. Significance of INHBA expression in human colorectal cancer. Okano M, Yamamoto H, Ohkuma H, Kano Y, Kim H, Nishikawa S, Konno M, Kawamoto K, Haraguchi N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Sekimoto M, Doki Y, Mori M, Ishii H. Oncol Rep. 2013 Dec;30(6):2903-8.
121. CD49f-positive cell population efficiently enriches colon cancer-initiating cells. Haraguchi N, Ishii H, Mimori K, Ohta K, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Int J Oncol. 2013 Aug;43(2):425-30.
120. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Takahashi Y, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Ishibashi M, Takano Y, Akiyoshi S, Iwaya T, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Anticancer Res. 2013 May;33(5):1927-34.
119. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, Ohue M, Ohnishi T, Tanaka N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Cancer Chemother Pharmacol. 2013 Jun;71(6):1657-63.
118. Depletion of JARID1B induces cellular senescence in human colorectal cancer. Ohta K, Haraguchi N, Kano Y, Kagawa Y, Konno M, Nishikawa S, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Noguchi Y, Ozaki M, Kudo T, Sakai D, Satoh T, Fukami M, Ishii M, Yamamoto H, Doki Y, Mori M, Ishii H. Int J Oncol. 2013 Apr;42(4):1212-8. - 117. C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer. Oshiro R, Yamamoto H, Takahashi H, Ohtsuka M, Wu X, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Sekimoto M, Matsuura N, Doki Y, Mori M. Cancer Sci. 2012 Jun;103(6):1155-64.
116. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, Tanaka F, Shibata K, Sekimoto M, Ishii H, Doki Y, Mori M. Oncology. 2012;82(4):205-12.
115. Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Yamada D, Kobayashi S, Yamamoto H, Tomimaru Y, Noda T, Uemura M, Wada H, Marubashi S, Eguchi H, Tanemura M, Doki Y, Mori M, Nagano H. Ann Surg Oncol. 2012 Jul;19 Suppl 3:S355-64.
114. microRNA-181a is associated with poor prognosis of colorectal cancer. Nishimura J, Handa R, Yamamoto H, Tanaka F, Shibata K, Mimori K, Takemasa I, Mizushima T, Ikeda M, Sekimoto M, Ishii H, Doki Y, Mori M. Oncol Rep. 2012 Dec;28(6):2221-6.
113. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Noda T, Yamamoto H, Takemasa I, Yamada D, Uemura M, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Liver Int. 2012 Jan;32(1):110-8.
112. Biological and clinical availability of adipose-derived stem cells for pelvic dead space repair.Takahashi H, Haraguchi N, Nishikawa S, Miyazaki S, Suzuki Y, Mizushima T, Nishimura J, Takemasa I, Yamamoto H, Mimori K, Ishii H, Doki Y, Mori M. Stem Cells Transl Med. 2012 Nov;1(11):803-10.
111. The features of late local recurrences following curative surgery for rectal cancer. Uemura M, Ikeda M, Sekimoto M, Noura S, Ohue M, Mizushima T, Yamamoto H, Takemasa I, Yano M, Ishikawa O, Doki Y, Mori M.Hepatogastroenterology. 2012 Sep;59(118):1800-3.
110. Laparoscopic bladder-preserving surgery for enterovesical fistula complicated with benign gastrointestinal disease. Mizushima T, Ikeda M, Sekimoto M, Yamamoto H, Doki Y, Mori M. Case Rep Gastroenterol. 2012 May;6(2):279-84.
109. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M. Ann Surg Oncol. 2012 Sep;19(9):3065-71.
108. Intraluminal migration of a spacer with small bowel obstruction: a case report of rare complication. Ogino T, Sekimoto M, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Doki Y, Mori M. World J Surg Oncol. 2012 Feb 6;10:30.
107. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Kim HM, Haraguchi N, Ishii H, Ohkuma M, Okano M, Mimori K, Eguchi H, Yamamoto H, Nagano H, Sekimoto M, Doki Y, Mori M. Ann Surg Oncol. 2012 Jul;19 Suppl 3:S539-48. - 106. OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: results from a multicenter clinical performance study in Japan. Yamamoto H, Sekimoto M, Oya M, Yamamoto N, Konishi F, Sasaki J, Yamada S, Taniyama K, Tominaga H, Tsujimoto M, Akamatsu H, Yanagisawa A, Sakakura C, Kato Y, Matsuura N. Ann Surg Oncol. 2011 Jul;18(7):1891-8.
105. Hypoxia-inducible adrenomedullin in colorectal cancer. Uemura M, Yamamoto H, Takemasa I, Mimori K, Mizushima T, Ikeda M, Sekimoto M, Doki Y, Mori M. Anticancer Res. 2011 Feb;31(2):507-14.
104. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Yamamoto H, Sekimoto M, Doki Y, Mori M. Ann Surg Oncol. 2011 Apr;18(4):1166-74.
103. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S, Tanemura M, Mimori K, Tanaka F, Saito T, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M. Cell Stem Cell. 2011 Jun 3;8(6):633-8.
102. Clinicopathological assessment of locally recurrent rectal cancer and relation to local re-recurrence. Uemura M, Ikeda M, Yamamoto H, Kitani K, Tokuoka M, Matsuda K, Hata Y, Mizushima T, Takemasa I, Sekimoto M, Hosokawa K, Matsuura N, Doki Y, Mori M. Ann Surg Oncol. 2011 Apr;18(4):1015-22.
101. Laparoscopic lymph node dissection around the inferior mesenteric artery with preservation of the left colic artery. Sekimoto M, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Doki Y, Mori M. Surg Endosc. 2011 Mar;25(3):861-6.
100. The significance of PITX2 overexpression in human colorectal cancer. Hirose H, Ishii H, Mimori K, Tanaka F, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M. Ann Surg Oncol. 2011 Oct;18(10):3005-12.
99. Heterogeneity of colorectal cancers and extraction of discriminator gene signatures for personalized prediction of prognosis. M Miyake, I Takemasa, R Matoba, M Tanino, S Niijima, M Ikeda, H Yamamoto, M Sekimoto, S Kuhara, T Okayama, M Monden, K Matsubara, M Mori. Int J Oncol. 2011; Oct;39(4):781-9.
98. Anal metastasis of colorectal carcinoma origin: implications for diagnosis and treatment strategy. Takahashi H, Ikeda M, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Mori M.Dis Colon Rectum. 2011 Apr;54(4):472-81. - 97. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Uemura M, Yamamoto H, Takemasa I, Mimori K, Hemmi H, Mizushima T, Ikeda M, Sekimoto M, Matsuura N, Doki Y, Mori M. Clin Cancer Res. 2010 Sep 15;16(18):4636-46.
96. Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer. Konishi K, Yamamoto H, Mimori K, Takemasa I, Mizushima T, Ikeda M, Sekimoto M, Matsuura N, Takao T, Doki Y, Mori M. Cancer Sci. 2010 Oct;101(10):2269-77.
95. Feasibility of end-to-anterior wall anastomosis in conversion of the double-stapling technique during laparoscopically assisted surgery. Yamamoto H, Sekimoto M, Uemura M, Miyoshi N, Haraguchi N, Takemasa I, Nomura M, Mizushima T, Ikeda M, Doki Y, Mori M. Surg Endosc. 2010 Sep;24(9):2178-81.
94. Minute liver metastases from a rectal carcinoid: A case report and review. Yamamoto H, Hemmi H, Gu JY, Sekimoto M, Doki Y, Mori M. World J Gastrointest Surg. 2010 Mar 27;2(3):89-94.
93. Risk factors for postoperative delirium in elderly patients with colorectal cancer. Tei M, Ikeda M, Haraguchi N, Takemasa I, Mizushima T, Ishii H, Yamamoto H, Sekimoto M, Doki Y, Mori M. Surg Endosc. 2010 Sep;24(9):2135-9.
92. Video. Transumbilical single-incision laparoscopic surgery for sigmoid colon cancer. Takemasa I, Sekimoto M, Ikeda M, Mizushima T, Yamamoto H, Doki Y, Mori M. Surg Endosc. 2010 Sep;24(9):2321.
91. Laparoscopic reoperation of anastomotic leakage after a laparoscopic low anterior resection of the rectum. Sekimoto M, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Doki Y, Mori M. Int J Colorectal Dis. 2010 May;25(5):665-6. - 90. Cancer cells survive with survivin. Yamamoto H, Ngan CY, Monden M. Cancer Sci. 2008 Sep;99(9):1709-14.
89. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. BMC Cancer. 2009 Oct 12;9:361.
88. Overexpression of MT1-MMP is insufficient to increase experimental liver metastasis of human colon cancer cells. Yamamoto H, Noura S, Okami J, Uemura M, Takemasa I, Ikeda M, Ishii H, Sekimoto M, Matsuura N, Monden M, Mori M. Int J Mol Med. 2008 Dec;22(6):757-61.
87. Prevention of severe pelvic abscess formation following extended radical surgery for locally recurrent rectal cancer. Uemura M, Ikeda M, Sekimoto M, Haraguchi N, Mizushima T, Yamamoto H, Takemasa I, Ishii H, Mori M. Ann Surg Oncol. 2009 Aug;16(8):2204-10.
86. Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy. Danno K, Ikeda M, Sekimoto M, Sugimoto T, Takemasa I, Yamamoto H, Doki Y, Monden M, Mori M. Surgery. 2009 May;145(5):457-64; discussion 465-6. - 85. Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Ezumi K, Yamamoto H, Murata K, Higashiyama M, Damdinsuren B, Nakamura Y, Kyo N, Okami J, Ngan CY, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Nojima H, Monden M. Clin Cancer Res. 2008 Feb 1;14(3):677-84.
84. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, Ikeda M, Takahashi-Yanaga F, Sasaguri T, Sekimoto M, Matsuura N, Monden M. Cancer Sci. 2008 Jan;99(1):129-39.
83. Overexpression of connexin 26 in carcinoma of the pancreas. Kyo N, Yamamoto H, Takeda Y, Ezumi K, Ngan CY, Terayama M, Miyake M, Takemasa I, Ikeda M, Doki Y, Dono K, Sekimoto M, Nojima H, Monden M. Oncol Rep. 2008 Mar;19(3):627-31.
82. Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case. Ezumi K, Yamamoto H, Takemasa I, Nomura M, Ikeda M, Sekimoto M, Monden M. Jpn J Clin Oncol. 2008 Mar;38(3):222-6.
81. CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells. Xu X, Yamamoto H, Liu G, Ito Y, Ngan CY, Kondo M, Nagano H, Dono K, Sekimoto M, Monden M. Int J Mol Med. 2008 Feb;21(2):145-52.
80. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Zhang Y, Fujiwara Y, Doki Y, Takiguchi S, Yasuda T, Miyata H, Yamazaki M, Ngan CY, Yamamoto H, Ma Q, Monden M. Oncology. 2008;75(1-2):17-26.
79. Gene expression of colorectal cancer: preoperative genetic diagnosis using endoscopic biopsies. Komori T, Takemasa I, Yamasaki M, Motoori M, Kato T, Kikkawa N, Kawaguchi N, Ikeda M, Yamamoto H, Sekimoto M, Matsubara K, Matsuura N, Monden M. Int J Oncol. 2008 Feb;32(2):367-75.
- 78. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Clin Cancer Res. 2007 Apr 1;13(7):2082-90.
77. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Ngan CY, Yamamoto H, Seshimo I, Tsujino T, Man-i M, Ikeda JI, Konishi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Br J Cancer. 2007 Mar 26;96(6):986-92.
76. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. Ngan CY, Yamamoto H, Seshimo I, Ezumi K, Terayama M, Hemmi H, Takemasa I, Ikeda M, Sekimoto M, Monden M. J Surg Oncol. 2007 Jun 15;95(8):652-62.
75. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Damdinsuren B, Nagano H, Wada H, Kondo M, Ota H, Nakamura M, Noda T, Natsag J, Yamamoto H, Doki Y, Umeshita K, Dono K, Nakamori S, Sakon M, Monden M. Int J Oncol. 2007 Jan;30(1):201-8.
74. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Wada H, Nagano H, Yamamoto H, Arai I, Ota H, Nakamura M, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Nakamori S, Sakon M, Monden M. Oncol Rep. 2007 Oct;18(4):801-9.
73. Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasion. Arai I, Nagano H, Kondo M, Yamamoto H, Hiraoka N, Sugita Y, Ota H, Yoshioka S, Nakamura M, Wada H, Damdinsuren B, Kato H, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M. Hepatogastroenterology. 2007 Jan-Feb;54(73):167-71.
72. Total splenic vein thrombosis after laparoscopic splenectomy: a possible candidate for treatment. Ikeda M, Sekimoto M, Takiguchi S, Yasui M, Danno K, Fujie Y, Kitani K, Seki Y, Hata T, Shingai T, Takemasa I, Ikenaga M, Yamamoto H, Ohue M, Monden M. Am J Surg. 2007 Jan;193(1):21-5.
71. Castleman's disease of the rectum: report of a case. Hata T, Ikeda M, Ikenaga M, Yasui M, Shingai T, Yamamoto H, Ohue M, Sekimoto M, Hoshida Y, Aozasa K, Monden M. Dis Colon Rectum. 2007 Mar;50(3):389-94. - 70. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, Weinstein IB, Monden M. Clin Cancer Res. 2006 Aug 1;12(15):4720-9.
69. Construction of a novel DNA decoy that inhibits the oncogenic beta-catenin/T-cell factor pathway. Seki Y, Yamamoto H, Ngan CY, Yasui M, Tomita N, Kitani K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Albanese C, Kaneda Y, Pestell RG, Monden M. Mol Cancer Ther. 2006 Apr;5(4):985-94.
68. Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Br J Cancer. 2006 Oct 9;95(7):889-95.
67. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, Tatsumi M, Sekimoto M, Hatazawa J, Nishimura T, Monden M. Dig Dis Sci. 2006 Dec;51(12):2198-205.
66. Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Gu J, Yamamoto H, Lu X, Ngan CY, Tsujino T, Konishi K, Takemasa I, Ikeda M, Nagata H, Hashimoto S, Matsuzaki T, Sekimoto M, Takagi A, Monden M. Digestion. 2006;74(1):19-27.
65. Expression and mutation of SMAD4 in poorly differentiated carcinoma and signet-ring cell carcinoma of the colorectum. Seshimo I, Yamamoto H, Mishima H, Kurata A, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Fukushima T, Tsujinaka T, Sekimoto M, Kikkawa N, Takenoshita S, Monden M .J Exp Clin Cancer Res. 2006 Sep;25(3):433-42.
64. Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case. Fujie Y, Ikeda M, Seshimo I, Ezumi K, Hata T, Shingai T, Yasui M, Takayama O, Fukunaga H, Ikenaga M, Takemasa I, Yamamoto H, Ohue M, Sekimoto M, Hirota S, Monden M. Surg Today. 2006;36(12):1133-8.
63. Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer. Yasui M, Ikeda M, Sekimoto M, Yamamoto H, Takemasa I, Ueda T, Shimizu J, Fukunaga M, Suzuki O, Inoue T, Monden M. World J Surg Oncol. 2006 Nov 22;4:83.
62. Single-photon emission computed tomography in the screening for postoperative pulmonary embolism. Hata T, Ikeda M, Nakamori S, Suzuki R, Kim T, Yasui M, Takemasa I, Ikenaga M, Yamamoto H, Ohue M, Murakami T, Sekimoto M, Sakon M, Monden M. Dig Dis Sci. 2006 Nov;51(11):2073-80.
61. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K, Monden M. Liver Int. 2006 May;26(4):414-23.
60. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Urano N, Fujiwara Y, Doki Y, Tsujie M, Yamamoto H, Miyata H, Takiguchi S, Yasuda T, Yano M, Monden M. Gastric Cancer. 2006;9(1):44-9.
59. Hypoxia-induced up-regulation of angiopoietin-2 in colorectal cancer. Gu J, Yamamoto H, Ogawa M, Ngan CY, Danno K, Hemmi H, Kyo N, Takemasa I, Ikeda M, Sekimoto M, Monden M. Oncol Rep. 2006 Apr;15(4):779-83.
58. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, Ota H, Yoshioka S, Kato H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Wakasa K, Monden M. Oncol Rep. 2006 Mar;15(3):525-32. - 57. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Hata T, Yamamoto H, Ngan CY, Koi M, Takagi A, Damdinsuren B, Yasui M, Fujie Y, Matsuzaki T, Hemmi H, Xu X, Kitani K, Seki Y, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Mol Cancer Ther. 2005 Oct;4(10):1585-94.
56. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Jpn J Clin Oncol. 2005 Aug;35(8):453-63.
55. Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Kim BN, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan CY, Fujie Y, Ogawa M, Hata T, Ikeda M, Ohue M, Sekimoto M, Monden T, Matsuura N, Monden M. Int J Oncol. 2005 May;26(5):1217-26.
54. Effects of p21cip1/waf1 overexpression on growth, apoptosis and differentiation in human colon carcinoma cells. Izawa H, Yamamoto H, Damdinsuren B, Ikeda K, Tsujie M, Suzuki R, Kitani K, Seki Y, Hayashi T, Takemasa I, Ikeda M, Ohue M, Sekimoto M, Monden T, Monden M. Int J Oncol. 2005 Jul;27(1):69-76.
53. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Kondo M, Nagano H, Wada H, Damdinsuren B, Yamamoto H, Hiraoka N, Eguchi H, Miyamoto A, Yamamoto T, Ota H, Nakamura M, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M, Monden M. Clin Cancer Res. 2005 Feb 1;11(3):1277-86.
52. Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I, Takayama O, Yamamoto H, Ohue M, Tatsumi M, Hatazawa J, Ikenaga M, Nishimura T, Monden M. Ann Surg Oncol. 2005 Jul;12(7):561-9.
51. Changes over time in thymidine phosphorylase and dihydropyrimidine dehydrogenase when colon cancer samples are left at room temperature. Ishida H, Tatsuta M, Yamamoto H, Furukawa H, Masutani S, Takemoto H, Munakata S, Miwa H, Sekimoto M, Monden M. Cancer Lett. 2005 May 10;222(1):107-12.
50. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ikeda M, Sekimoto M, Takiguchi S, Kubota M, Ikenaga M, Yamamoto H, Fujiwara Y, Ohue M, Yasuda T, Imamura H, Tatsuta M, Yano M, Furukawa H, Monden M. Ann Surg. 2005 Feb;241(2):208-16.
49. Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Damdinsuren B, Nagano H, Kondo M, Yamamoto H, Hiraoka N, Yamamoto T, Marubashi S, Miyamoto A, Umeshita K, Dono K, Nakamori S, Wakasa K, Sakon M, Monden M. Int J Oncol. 2005 Feb;26(2):319-27. - 48. Hepatic expression of ANG2 RNA in metastatic colorectal cancer. Ogawa M, Yamamoto H, Nagano H, Miyake Y, Sugita Y, Hata T, Kim BN, Ngan CY, Damdinsuren B, Ikenaga M, Ikeda M, Ohue M, Nakamori S, Sekimoto M, Sakon M, Matsuura N, Monden M. Hepatology. 2004 Feb;39(2):528-39.
47. Application of RT-PCR to clinical diagnosis of micrometastasis of colorectal cancer: A translational research study. Takayama O, Yamamoto H, Ikeda K, Ishida H, Kato T, Okuyama M, Kanou T, Fukunaga M, Tominaga S, Morita S, Fujie Y, Fukunaga H, Ikenaga M, Ikeda M, Ohue M, Sekimoto M, Kikkawa N, Monden M. Int J Oncol. 2004 Sep;25(3):597-604.
46. Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto H, Fujita S, Kanato K, Ito K, Jomgeow T, Kawakami M, Tsuboi A, Shirakata T, Nishida S, Hosen N, Oka Y, Aozasa K, Monden M, Sugiyama H. Anticancer Res. 2004 Sep-Oct;24(5B):3103-8.
45. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, Yamamoto H, Sakon M, Nezu R, Kawano K, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Yoshikawa K, Aozasa K, Monden M, Sugiyama H. Cancer Sci. 2004 Jul;95(7):583-7.
44. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Xu X, Sakon M, Nagano H, Hiraoka N, Yamamoto H, Hayashi N, Dono K, Nakamori S, Umeshita K, Ito Y, Matsuura N, Monden M. Oncol Rep. 2004 Jan;11(1):25-32.
- 43. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M. Gastroenterology. 2003 Aug;125(2):556-71.
42. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Xu X, Yamamoto H, Sakon M, Yasui M, Ngan CY, Fukunaga H, Morita T, Ogawa M, Nagano H, Nakamori S, Sekimoto M, Matsuura N, Monden M. Clin Cancer Res. 2003 May;9(5):1764-72.
41. Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor. Okami J, Nakamori S, Hiraoka N, Tsujie M, Hayashi N, Yamamoto H, Fujiwara Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Clin Exp Metastasis. 2003;20(7):577-84.
40. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, Abeno S, Kiyotoh E, Jomgeow T, Sekimoto M, Nezu R, Yoshikawa Y, Inoue Y, Hosen N, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Souda S, Aozasa K, Monden M, Sugiyama H. Cancer Sci. 2003 Aug;94(8):712-7.
39. Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. Muro S, Takemasa I, Oba S, Matoba R, Ueno N, Maruyama C, Yamashita R, Sekimoto M, Yamamoto H, Nakamori S, Monden M, Ishii S, Kato K. Genome Biol. 2003;4(3):R21. - 38. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Takayama O, Fukunaga H, Miyake Y, Ikenaga M, Ikeda M, Sekimoto M, Matsuura N, Monden M. J Clin Oncol. 2002 Oct 15;20(20):4232-41.
37. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Noura S, Yamamoto H, Miyake Y, Kim Bn, Takayama O, Seshimo I, Ikenaga M, Ikeda M, Sekimoto M, Matsuura N, Monden M. Clin Cancer Res. 2002 Mar;8(3):759-67.
36. Molecular analysis of diminutive, flat, depressed colorectal lesions: are they precursors of polypoid adenoma or early stage carcinoma? Morita T, Tomita N, Ohue M, Sekimoto M, Yamamoto H, Ohnishi T, Tada M, Ikenaga M, Miyake Y, Sakita I, Tamaki Y, Matsuura N, Ito M, Monden M. Gastrointest Endosc. 2002 Nov;56(5):663-71.
35. An immunohistochemical study of cyclooxygenase (COX)-2 expression in endocrine tumors of the pancreas. Okami J, Nakamori S, Yamamoto H, Sakon M, Tsujie M, Hayashi N, Nagano H, Dono K, Umeshita K, Ishikawa O, Ohigashi H, Monden M. J Exp Clin Cancer Res. 2002 Dec;21(4):569-76.
34. Clinical relevance of fusion images using (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in local recurrence of rectal cancer. Fukunaga H, Sekimoto M, Tatsumi M, Ikenaga M, Ohue M, Seshimo I, Higuchi I, Takayama O, Yasui M, Ikeda M, Yamamoto H, Monden M. Int J Oncol. 2002 Apr;20(4):691-5.
33. Use of microsatellite analysis in young patients with colorectal cancer to identify those with hereditary nonpolyposis colorectal cancer. Ikenaga M, Tomita N, Sekimoto M, Ohue M, Yamamoto H, Miyake Y, Mishima H, Nishisho I, Kikkawa N, Monden M. J Surg Oncol. 2002 Mar;79(3):157-65.
32. Analysis of cyclin D1 and CDK expression in colonic polyps containing neoplastic foci: a study of proteins extracted from paraffin sections. Izawa H, Yamamoto H, Ikeda M, Ikeda K, Fukunaga H, Yasui M, Ikenaga M, Sekimoto M, Monden T, Matsuura N, Monden M. Oncol Rep. 2002 Nov-Dec;9(6):1313-8. - 31. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, Nagano H, Umeshita K, Sakon M, Matsuura N, Nakamori S, Monden M. Hepatology. 2001 Oct;34(4 Pt 1):638-50.
30. Expression of second class of KIP protein p57KIP2 in human colorectal carcinoma. Noura S, Yamamoto H, Sekimoto M, Takemasa I, Miyake Y, Ikenaga M, Matsuura N, Monden M. Int J Oncol. 2001 Jul;19(1):39-47.
29. Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells. Miyata H, Doki Y, Yamamoto H, Kishi K, Takemoto H, Fujiwara Y, Yasuda T, Yano M, Inoue M, Shiozaki H, Weinstein IB, Monden M. Cancer Res. 2001 Apr 1;61(7):3188-93.
28. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. I Takemasa 1, H Higuchi, H Yamamoto, M Sekimoto, N Tomita, S Nakamori, R Matoba, M Monden, K Matsubara. Biochem Biophys Res Commun. 2001;285(5):1244-9.
27. Human stomach-specific gene, CA11, is down-regulated in gastric cancer. Shiozaki K, Nakamori S, Tsujie M, Okami J, Yamamoto H, Nagano H, Dono K, Umeshita K, Sakon M, Furukawa H, Hiratsuka M, Kasugai T, Ishiguro S, Monden M. Int J Oncol. 2001 Oct;19(4):701-7.
26. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, Fujiwara Y, Yano M, Miyata H, Kishi K, Nakagawa H, Shamma A, Monden M. Br J Cancer. 2001 Aug 3;85(3):412-21.
25. Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. Okada Y, Fujiwara Y, Yamamoto H, Sugita Y, Yasuda T, Doki Y, Tamura S, Yano M, Shiozaki H, Matsuura N, Monden M. Cancer. 2001 Oct 15;92(8):2056-64.
24. Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. M Ooka, Y Tamaki, I Sakita, Y Fujiwara, H Yamamoto, Y Miyake, M Sekimoto, M Ohue, Y Sugita, Y Miyoshi, N Ikeda, S Noguchi, M Monden. Breast Cancer Res Treat. 2001;67(2):169-75.
23. Extensive micrometastases to lymph nodes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping. Y Miyake 1, H Yamamoto, Y Fujiwara, M Ohue, Y Sugita, N Tomita, M Sekimoto, N Matsuura, H Shiozaki, M Monden. Clin Cancer Res. 2001;7(5):1350-7. - 22. Quantification of micrometastases in lymph nodes of colorectal cancer using real-time fluorescence polymerase chain reaction. Y Miyake, Y Fujiwara, M Ohue, H Yamamoto, Y Sugita, N Tomita, M Sekimoto, H Shiozaki, M Monden. Int J Oncol. 2000；Feb;16(2):289-93.
21. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H, Monden M. Clin Cancer Res. 2000 Apr;6(4):1229-38.
20. Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Eguchi H, Nagano H, Yamamoto H, Miyamoto A, Kondo M, Dono K, Nakamori S, Umeshita K, Sakon M, Monden M. Clin Cancer Res. 2000 Jul;6(7):2881-90.
19. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. I Takemasa, H Yamamoto, M Sekimoto, M Ohue, S Noura, Y Miyake, T Matsumoto, T Aihara, N Tomita, Y Tamaki, I Sakita, N Kikkawa, N Matsuura, H Shiozaki, M Monden. Cancer Res. 2000; 60(11):3043-50.
18. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Tsujie M, Yamamoto H, Tomita N, Sugita Y, Ohue M, Sakita I, Tamaki Y, Sekimoto M, Doki Y, Inoue M, Matsuura N, Monden T, Shiozaki H, Monden M. Oncology. 2000 Feb;58(2):126-36.
17. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Miyata H, Doki Y, Shiozaki H, Inoue M, Yano M, Fujiwara Y, Yamamoto H, Nishioka K, Kishi K, Monden M. Clin Cancer Res. 2000 Dec;6(12):4859-65.
16. Expression of interferon alpha/beta receptor in human hepatocellular carcinoma. Kondo M, Nagano H, Sakon M, Yamamoto H, Morimoto O, Arai I, Miyamoto A, Eguchi H, Dono K, Nakamori S, Umeshita K, Wakasa K, Ohmoto Y, Monden M. Int J Oncol. 2000 Jul;17(1):83-8.
15. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. M Ooka, I Sakita, Y Fujiwara, Y Tamaki, H Yamamoto, T Aihara, M Miyazaki, M Kadota, N Masuda, Y Sugita, K Iwao, M Monden. Oncol Rep. 2000;7(3):561-6. - 14. Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells. Yamamoto H, Soh JW, Shirin H, Xing WQ, Lim JT, Yao Y, Slosberg E, Tomita N, Schieren I, Weinstein IB. Oncogene. 1999 Jan 7;18(1):103-15.
13. Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Yamamoto H, Soh JW, Monden T, Klein MG, Zhang LM, Shirin H, Arber N, Tomita N, Schieren I, Stein CA, Weinstein IB. Clin Cancer Res. 1999 Jul;5(7):1805-15.
12. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M. Clin Cancer Res. 1999 Dec;5(12):4005-12.
11. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori S, Monden M. Clin Cancer Res. 1999 Aug;5(8):2018-24.
10. Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Arber N, Hibshoosh H, Yasui W, Neugut AI, Hibshoosh A, Yao Y, Sgambato A, Yamamoto H, Shapira I, Rosenman D, Fabian I, Weinstein IB, Tahara E, Holt PR. Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1101-5.
9. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB. Biochem Pharmacol. 1999 Oct 1;58(7):1097-107.
8. Helicobacter pylori inhibits the G1 to S transition in AGS gastric epithelial cells. Shirin H, Sordillo EM, Oh SH, Yamamoto H, Delohery T, Weinstein IB, Moss SF. Cancer Res. 1999 May 15;59(10):2277-81. - 7. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB. Cancer Res. 1998 Jan 1;58(1):114-22.
6. Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Yamamoto H, Monden T, Miyoshi H, Izawa H, Ikeda K, Tsujie M, Ohnishi T, Sekimoto M, Tomita N, Monden M. Int J Oncol. 1998 Aug;13(2):233-9.
5. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Weinstein IB, Begemann M, Zhou P, Han EK, Sgambato A, Doki Y, Arber N, Ciaparrone M, Yamamoto H. Clin Cancer Res. 1997 Dec;3(12 Pt 2):2696-702.
4. A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Ohnishi T, Tomita N, Monden T, Ohue M, Yana I, Takami K, Yamamoto H, Yagyu T, Kikkawa N, Shimano T, Monden M. Br J Cancer. 1997;75(3):341-7.
3. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Han EK, Arber N, Yamamoto H, Lim JT, Delohery T, Pamukcu R, Piazza GA, Xing WQ, Weinstein IB. Breast Cancer Res Treat. 1998 Apr;48(3):195-203. - 2. Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. Yamamoto H, Monden T, Ikeda K, Izawa H, Fukuda K, Fukunaga M, Tomita N, Shimano T, Shiozaki H, Monden M. Br J Cancer. 1995 Jun;71(6):1231-6.
- 1. Immunohistochemical study of retinoblastoma gene-expression in colorectal carcinomas. Fukuda K, Monden T, Yamamoto H, Ohue M, Fukunaga M, Tomita N, Shimano T, Mori T. Int J Oncol. 1994 Jan;4(1):117-21.
- 1. [Dendritic Cell Therapy with Neoantigens and Oncoantigens].Takeda T, Takeda T, Kubota Y, Kubota A, Hattori N, Takeda H, Hasegawa T, Nakamura J, Yokoyama Y, Yamamoto H. Gan To Kagaku Ryoho. 2020 Nov;47(11):1621-1623.
2. [Two cases of rectal neuroendocrine carcinoma associated with long-standing ulcerative colitis]. Miyazaki H, Mizushima T, Miyoshi N, Takahashi H, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mori M, Doki Y.Nihon Shokakibyo Gakkai Zasshi. 2020;117(6):521-531.
3. [Combination of Immunotherapy and Hyperthermia]. Kubota Y, Takeda T, Takeda T, Noda T, Hattori N, Nakamura K, Yasuda T, Hasegawa T, Yokoyama Y, Yamamoto H, Takeda H. Gan To Kagaku Ryoho. 2019 Oct;46(10):1605-1607.
4. [Enhancing Antitumor Effects Using Hyperthermia (Including Immune Checkpoint Inhibitor)]. Takeda T, Kubota Y, Takeda T, Nakano Y, Nogami Y, Honjoh I, Takeda H, Yokoyama Y, Yamamoto H. Gan To Kagaku Ryoho. 2018 Oct;45(10): 1479-1481.
5. Effects of Immune Checkpoint Inhibitor Combined with Dendritic Cell Therapy and Hyperthermia]. Takeda T, Kubota Y, Takeda T, Tanaka C, Morita S, Hattori N, Takeda H, Yokoyama Y, Yamamoto H. Gan To Kagaku Ryoho. 2018 Oct;45(10): 1472-1474
6. [A Case of Rectal Cancer with Multiple Pulmonary and Liver Metastases Could Be Resected through Chemotherapy]. Nomura M, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Yamamoto H, Mizushima T, Doki Y, Mori M.Gan To Kagaku Ryoho. 2018 Jan;45(1): 169-171.
7. [A Case of Resection of Para-Aortic Lymph Node Recurrence Three Years after Curative Surgery for Ascending Colon Cancer]. Nishizawa Y, Hata T, Takahashi H, Haraguchi N, Nishimura J, Matsuda C, Mizushima T, Yamamoto H, Doki Y, Mori M. Gan To Kagaku Ryoho. 2016 Nov;43(12):2323-2325.
8. [Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report]. Ohara N, Haraguchi N, Kudo T, Takahashi H, Nishimura J, Hata T, Matsuda C, Satoh T, Mizushima T,Yamamoto H, Doki Y, Mori M. Gan To Kagaku Ryoho. 2016 Nov;43(12):1803-1805.
9. [A Case of Concurrent Cancer in a Giant Rectal Villous Adenoma That Resulted in Extensive Lymph Node Metastases]. Ohtsuka M, Hata T, Hiraki M, Takeyama H, Nonaka R, Uemura M, Nishimura J, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Gan To Kagaku Ryoho. 2015 Jun;42(6):747-50.
10. [A case of solitary fibrous tumor from the greater omentum resected via laparoscopic surgery]. Osawa H, Nishimura J, Inoue A, Ueda M, Mokutani Y, Miyo M, Naito A, Hamabe A, Hiraki M, Matsumura T, Munakata K, Ogino T, Takahashi Y, Uemura M, Hata T, Takemasa I, Mizushima T,Yamamoto H, Doki Y, Mori M. Gan To Kagaku Ryoho. 2014 Nov;41(12):2493-5.
11. [A case of pathological complete response with neoadjuvant XELOX chemotherapy for locally advanced rectal cancer]. Kitahara T, Takemasa I, Inoue A, Osawa H, Miyo M, Mokutani Y, Ogawa H, Naito A, Hamabe A, Hiraki M, Munakata K, Uemura M, Nishimura J, Hata T, Mizushima T, Yamamoto H, Doki Y, Mori M. Gan To Kagaku Ryoho. 2014 Nov;41(12):1569-71.
12. [Preoperative evaluation of laparoscopic surgery for colorectal cancer with a virtual three-dimensional multi-imaging]. Takemasa I, Yamamoto H, Doki Y, Mori M. Nihon Rinsho. 2014 Jan;72(1):77-81.
13. [Lymph node micrometastases in colorectal cancer]. Yamamoto H, Doki Y, Mori M.Nihon Geka Gakkai Zasshi. 2013 Jan;114(1):17-21.
14. [Curative laparoscopic surgery performed after neoadjuvant chemotherapy for locally advanced rectal cancer invading into the vagina]. Ohtsuka M, Mizushima T, Ohta K, Nishimura J, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M. Gan To Kagaku Ryoho. 2011 Nov;38(12):2262-4.
15. [Two cases of curative resection for locally recurrent rectal cancer with high-level sacrectomy after preoperative chemoradiation therapy (CRT)]. Ohta K, Ikeda M, Kagawa Y, Ohtsuka M, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Mor M. Gan To Kagaku Ryoho. 2011 Nov;38(12):1992-4.
16. [A case of lateral lymph node metastasis of submucosal rectal cancer]. Yamashita S, Ikeda M, Kim HM, Hirose H, Kagawa Y, Takemasa I, Mizushima T, Ishii H, Yamamoto H, Sekimoto M, Doki Y, Mori M. Gan To Kagaku Ryoho. 2010 Nov;37(12):2629-31.
17. [An experience of curative resection of local recurrent rectal cancer with high-level sacrectomy after preoperative chemo-radiation therapy]. Kagawa Y, Ikeda M, Yamashita S, Kim HM, Hirose H, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Mori M. Gan To Kagaku Ryoho. 2010 Nov;37(12):2617-9.
18. [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]. Kim HM, Ikeda M, Okano M, Miyoshi N, Hirose H, Yamashita S, Takemasa I, Mizushima T, Yamamoto H, Sekimoto M, Doki Y, Mori M. Gan To Kagaku Ryoho. 2010 Nov;37(12):2548-50.
19. [A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy]. Hirose H, Ikeda M, Miyoshi N, Kim HM, Okano M, Uemura M, Yamashita S, Takemasa I, Mizushima T, Yamamoto H, Ishii H, Sekimoto M, Doki Y, Mori M. Gan To Kagaku Ryoho. 2010 Nov;37(12):2545-7.
20. [Cancer stem cells in solid tumors]. Hirose H, Yamamoto H, Miyoshi N, Uemura M, Miyazaki S, Takahashi H, Takemasa I, Mizushima T, Ikeda M, Ishii H, Sekimoto M, Doki Y, Mori M. Gan To Kagaku Ryoho. 2010 Dec;37(13):2809-12.
21. [Case report--Complete response of liver metastasis of rectal cancer after combination chemotherapy of CPT-11 + UFT-E]. Hata T, Ikeda M, Ikenaga M, Seshimo I, Takayama O, Fukunaga H, Yasui M, Yamamoto H, Ohue M, Sekimoto M, Monden M. Gan To Kagaku Ryoho. 2004 Oct;31(11):1702-4.
22. [A case of curative resection of local recurrence after abdominosacral resection of recurrent rectal cancer based on the diagnosis of PET/CT fusion images]. Ohue M, Sekimoto M, Fukunaga H, Ikenaga M, Yamamoto H, Ikeda M, Yasui M, Takayama H, Hata Y, Kitani K, Seki Y, Hujie Y, Higuchi I, Monden M. Gan To Kagaku Ryoho. 2003 Oct;30(11):1829-32.
23. [A case of local recurrence of rectal cancer in which trans-sacral resection and perineal reconstruction by femoral posterior flap were performed]. Ikenaga M, Sekimoto M, Ohue M, Yamamoto H, Ikeda M, Fukunaga H, Nakai K, Yano K, Hosokawa K, Monden M. Gan To Kagaku Ryoho. 2003 Oct;30(11):1710-2.
24. [Molecular biology-based surgery for the future progress of cancer treatment]. Fujiwara Y, Yamamoto H, Monden M. Nihon Geka Gakkai Zasshi. 2002 Mar;103(3):278-83.
25. [Cyclin D, CDK4 and p16 expression in colorectal cancer]. Ikeda K, Monden T, Tsujie M, Izawa H, Yamamoto H, Ohnishi T, Ohue M, Sekimoto M, Tomita N, Monden M. Nihon Rinsho. 1996 Apr;54(4):1054-9.
26. [RB gene expression in gastrointestinal tract]. Monden T, Yamamoto H, Ikeda K, Izawa H, Tsujie M, Ohnishi T, Miyoshi Y, Sekimoto M, Tomita N, Monden M. Nihon Rinsho. 1996 Apr;54(4):965-71.
英文原著
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1995
1994
和文 Pubmed 収録分のみ
学会発表
-
2021年度
第30回 日本がん転移学会学術集会
1.山本浩文
核酸医療のための新しいリン酸カルシウム法の確立
第30回 日本がん転移学会学術集会 2021年7月.
2.木嶋仁美、横山雄起、河波志穂、窪田瑛佳、呉美喬、王佳き、三上浩司、南俊行、井上彬、木島貴志、山本浩文
肺癌のアンメットニーズを解決するmicroRNAの探索
第30回 日本がん転移学会学術集会 2021年7月.
3.横山雄起、高橋秀和、武田和、杉山真美、浅井香穂、波多豪、井上彬、三吉範克、植村守、山本浩文
大腸癌におけるLncRNA CCAT1発現制御メカニズムの解明
第30回 日本がん転移学会学術集会 2021年7月.
4.王佳き、横山雄起、廣瀬遥香、波多豪、大塚正久、井上彬、三吉範克、高橋秀和、植村守、山本浩文
MiR-1291は大腸癌細胞の癌幹細胞性を阻害する
第30回 日本がん転移学会学術集会 2021年7月.
5.浅井香穂、横山雄起、武田和、杉山真美、井上彬、波多豪、三吉範克、高橋秀和、植村守、山本浩文
大腸癌組織におけるKLF5とCCAT1の発現検討
第30回 日本がん転移学会学術集会 2021年7月.
6.河波志穂、森本祥悠、横山雄起、王佳き、大塚正久、井上彬、波多豪、高橋秀和、原口直紹、植村守、山本浩文
miR-4711-5pは大腸・膵癌細胞の幹細胞性質を抑制する
第30回 日本がん転移学会学術集会 2021年7月.
7.波多豪、三吉範克、藤野志季、荻野崇之、高橋秀和、植村守、水島恒和、土岐祐一郎、江口英利、山本浩文
OSNA法による大腸癌微小リンパ節転移の検出と臨床応用
第30回 日本がん転移学会学術集会 2021年7月.
8.市原もも子、高橋秀和、横山雄起、波多豪、藤野志季、荻野崇之、西田尚弘、三吉範克、植村守、水島恒和、土岐祐一郎、江口英利、山本浩文
Long non-coding RNA 01534の大腸癌における機能と予後に関する検討
第30回 日本がん転移学会学術集会 2021年7月.
第80回 日本癌学会学術総会
1.三吉範克、藤野志季、荻野崇之、高橋秀和、植村守、山本浩文、水島恒和、土岐祐一郎、江口英利
癌幹細胞の生み出す腫瘍均一性と臨床的治療抵抗性の獲得
第80回 日本癌学会学術総会 2021年9月.
2.吉村大士、高橋秀和、岩﨑真衣、波多豪、三吉範克、植村守、横山雄起、山本浩文
大腸癌の再発、予後マーカーとしてのC4.4Aタンパクの有用性についての検討
第80回 日本癌学会学術総会 2021年9月.
3.市原もも子、高橋秀和、横山雄起、浅井香穂、関戸悠紀、荻野崇之、三吉範克、植村守、土岐祐一郎、江口英利、山本浩文
小胞体ストレス応答における長鎖ノンコーディングRNA01534の関与
第80回 日本癌学会学術総会 2021年9月.
4.板倉弘明、奥崎大介、横山雄起、関戸悠紀、波多豪、荻野崇之、三吉範克、高橋秀和、植村守、土岐祐一郎、江口英利、山本浩文
大腸癌の発生・進展におけるMAF遺伝子の役割解明
第80回 日本癌学会学術総会 2021年9月.
5.知念良直、波多豪、関戸悠紀、荻野崇之、三吉範克、高橋秀和、植村守、山本浩文、土岐祐一郎、江口英利
大腸癌におけるHOXA5の発現意義
第80回 日本癌学会学術総会 2021年9月.
2020年度
第120回日本外科学会定期学術集会
1.市原もも子、森本祥悠、野村雅俊、井上彬、藤野志季、荻野崇之、高橋秀和、三吉範克、植村守、松田宙、森正樹、土岐祐一郎、山本浩文
大腸癌血中循環細胞の簡易検出方法の開発
第120回 日本外科学会定期学術集会・2020年8月.
2.板倉弘明、三吉範克、藤野志季、荻野崇之、高橋秀和、 植村守、松田宙、水島恒和、山本浩文、森正樹、土岐祐一郎
Deep learningを用いたAIによる大腸癌壁深達度診断の試み
第120回 日本外科学会定期学術集会・2020年8月.
3.辻村直人、畑泰司、藤野志季、三吉範克、高橋秀和、原口直紹、植村守、松田宙、山本浩文、森正樹、土岐祐一郎
当院における大腸癌pStageII-IIIに対するリンパ球-単球比（LMR）の意義
第120回 日本外科学会定期学術集会・2020年8月.
4.武田和、荻野崇之、藤野志季、三吉範克、高橋秀和、植村守、松田宙、山本浩文、水島恒和、森正樹、土岐祐一郎
抗TNFα抗体製剤のクローン病術後再発に対する影響
第120回 日本外科学会定期学術集会・2020年8月.
5.大塚正久、市原もも子、廣瀬遥香、高橋秀和、松田宙、赤松大樹、水島恒和、土岐祐一郎、山本浩文
大腸癌幹細胞関連長鎖非コードRNA LNC01534の機能的役割の解明
第120回 日本外科学会定期学術集会・2020年8月.
第58回 日本癌治療学会学術集会
板倉弘明、横山雄起、武田和、波多豪、大塚正久、藤野志季、荻野崇之、三吉範克、高橋秀和、植村守、原口直紹、水島恒和、土岐祐一郎、江口英利 、山本浩文
大腸癌における三次元ゲノム構造を介したKLF5遺伝子発現制御メカニズムの解明
第58回 日本癌治療学会学術集会・2020年10月.
第79回日本癌学会学術総会
1.市原もも子、横山雄起、森本祥悠、大塚正久、大原信福、藤野志季、荻野崇之、高橋秀和、三吉範克、植村守、水島恒和、山本浩文、土岐祐一郎、江口英利
LINC01534と大腸がんの予後との関係
第79回 日本癌学会学術総会・2020年10月.
2.王佳琦、廣瀬遥香、横山雄起、波多豪、井上彬、平木将之、大塚正久、高橋秀和、水島恒和、森正樹、山本浩文
MiR-1291は結腸癌細胞の癌幹細胞性を阻害する
第79回 日本癌学会学術総会・2020年10月.
3.横山雄起、武田和、藤田敏次、奥崎大介、杉山真美、浅井香穂、高橋秀和、藤井穂高、森正樹、山本浩文
大腸癌における三次元ゲノム構造を介したKLF5遺伝子発現制御メカニズム
第79回 日本癌学会学術総会・2020年10月.
4.窪田瑛佳、横山雄起、久保田結衣、武田和、森本祥悠、三吉範克、高橋秀和、長谷川武夫、武田力、山本浩文
大腸癌における温熱療法と免疫チェックポイント阻害剤併用療法の有用性
第79回 日本癌学会学術総会・2020年10月.
5.河波志穂、森本祥悠、横山雄起、大塚正久、井上彬、波多豪、高橋秀和、原口直紹、森正樹、山本浩文
miR-4711-5pは大腸癌細胞の幹細胞性質を抑制する
第79回 日本癌学会学術総会・2020年10月.
6.中根和昭、堤康嘉、横山雄起、森井英一、南雲サチ子、山本浩文
数理的アルゴリズムを用いたクロマチンパターンの定量評価
第79回 日本癌学会学術総会・2020年10月.
第75回日本大腸肛門病学会学術集会
1.板倉弘明、高橋秀和、森本祥悠、藤野志季、荻野崇之、三吉範克、植村守、山本浩文、水島恒和、土岐祐一郎、江口英利
術後CEA高値はハイリスクStageⅡの再発予測因子となる
第75回 日本大腸肛門病学会学術集会・2020年11月.
2.市原もも子、三吉範克、藤野志季、荻野崇之、高橋秀和、植村守、水島恒和、山本浩文、土岐祐一郎、江口英利
StageIII上行/横行結腸癌における主リンパ節転移の有無が予後に与える影響についての検討
第75回日本大腸肛門病学会学術集会・2020年11月.
2019年度
第40回癌免疫外科研究会
久保田結衣、武田力、武田和、野田剛広、服部宣明、中村華奈、安田知世、長谷川武夫、横山雄起、武田寛子、山本浩文
複合免疫療法と温熱療法 [口演]
第40回 癌免疫外科研究会、金沢、5月16日~17日、2019.
第21回関西ハイパーサーミア研究会
1.山本浩文
核酸研究の潮流と温熱療法への取り組み [特別講演]
第21回 関西ハイパーサーミア研究会、京都、6月22日、2019.
2.武田力、山本浩文
Eカドヘリンマトリックスによる大腸癌幹細胞性質の増強令和新時代の温熱療法の発展は (免疫チェックポイント阻害薬とネオアンチゲンの新時代において) [口演]
第21回 関西ハイパーサーミア研究会、京都、6月22日、2019.
3.安田知世、久保田結衣、横山雄起、廣瀬遥香、柴田理志、長谷川武夫、武田力、山本浩文
分子温熱治療の可能性 [口演]
第21回 関西ハイパーサーミア研究会、京都、6月22日、2019.
第28回日本がん転移学会学術総会
1.安田知世、久保田結衣、横山雄起、廣瀬遥香、柴田理志、長谷川武夫、武田力、山本浩文
分子温熱治療の可能性 [ワークショップ]
第28回 日本がん転移学会学術集会・総会、鹿児島、7月25日~26日、2019.
2.銭雅敏、横山雄起、田口真衣、廣瀬遥香、呉しん、山本浩文
Eカドヘリンマトリックスによる大腸癌幹細胞性質の増強 [ポスター]
第28回 日本がん転移学会学術集会・総会、鹿児島、7月25日~26日、2019.
3.横山雄起、武田和、北川公望、山本浩文
卵巣癌におけるBRD4を介したALDH1A1遺伝子発現制御メカニズムの解明 [ポスター]
第28回 日本がん転移学会学術集会・総会、鹿児島、7月25日~26日、2019.
4.北川公望、武田和、横山雄起、山本浩文
大腸癌におけるKLF5遺伝子発現制御メカニズムの解明 [ワークショップ]
第28回 日本がん転移学会学術集会・総会、鹿児島、7月25日~26日、2019.
5.廣瀬遥香、横山雄起、武田昂樹、呉しん、山本浩文
プロモーター作動性癌細胞可視化システムの構築 [ポスター]
第28回 日本がん転移学会学術集会・総会、鹿児島、7月25日~26日、2019.
第78回日本癌学会学術総会
1.五島碧、横山雄起、入江侑馬、廣瀬遥香、木島貴志、三好康雄、柴田理志、山本浩文
難治性癌に対する核酸医薬MIRTXの抗腫瘍効果の検討 [ポスター]
第78回 日本癌学会学術総会、京都、9月26日~28日、2019.
2.藤本彩花、森誠司、五島碧、横山雄起、松浦成昭、高田義一、山本浩文
FGF2とインテグリンがEMTに及ぼす影響 [口演]
第78回 日本癌学会学術総会、京都、9月26日~28日、2019.
3.杉山真美、横山雄起、武田和、北川公望、山本浩文
膵癌細胞に対するBETタンパク阻害剤JQ1の効果の検討 [ポスター]
第78回 日本癌学会学術総会、京都、9月26日~28日、2019.
4.岩﨑真衣、武田和、外山愛、大塚正久、横山雄起、廣瀬遥香、大西直、村田幸平、加藤健志、水島恒和、土岐祐一郎、山本浩文
C4.4A染色による大腸癌再発予測に関するvalidation study [シンポジウム]
第78回 日本癌学会学術総会、京都、9月26日~28日、2019.
5.田口真衣、横山雄起、銭雅敏、廣瀬遥香、呉しん、山本浩文
結腸癌細胞においてE-cadherin-Fcは上皮間葉転換を誘導し癌幹様特性を増強する [ポスター 日本語]
第78回 日本癌学会学術総会、京都、9月26日~28日、2019.
第30回日本消化器癌発生学会総会
1.久保田結衣、武田力、長谷川武夫、武田寛子、安田知世、横山雄起、山本浩文
温熱による細胞性免疫誘導と免疫チェックポイント阻害剤併用の意義 [ワークショップ]
第30回 日本消化器癌発生学会総会、横浜、11月7日~8日、2019.
2.松田美和、中根和昭、横山雄起、南雲サチ子、森井英一、山本浩文
ホモロジー概念を用いた大腸癌発生過程の数理学的病理診断 [シンポジウム]
第30回 日本消化器癌発生学会総会、横浜、11月7日~8日、2019.
3.外山愛、武田昂樹、波多豪、磯賢治、横山雄起、松田宙、水島恒和、土岐祐一郎、森正樹、山本浩文
大腸癌におけるc-MAF発現の意義 [ワークショップ]
第30回 日本消化器癌発生学会総会、横浜、11月7日~8日、2019.
4.入江侑馬、横山雄起、石川翔、銭雅敏、廣瀬遥香、山本浩文
膵癌細胞におけるmiR-29b-1-5pの抗腫瘍効果の検討 [ワークショップ]
第30回 日本消化器癌発生学会総会、横浜、11月7日~8日、2019.
第32回バイオセラピィ学会学術集会総会
武田力、久保田結衣、武田和、安田知世、窪田瑛佳、服部宣明、中村華奈、武田寛子、長谷川武夫、中村祐輔、横山雄起、山本浩文
ネオアンチゲン・免疫チェックポイント阻害剤そして温熱療法 [口演]
第32回 バイオセラピィ学会学術集会総会、岡山、11月28日~29日、2019.
第42回日本分子生物学会年会
藤本彩花、森誠司、五島碧、横山雄起、松浦成昭、山本浩文
FGF2とインテグリンの結合が乳腺上皮細胞のEMT進行に及ぼす影響 [ポスター]
第42回 日本分子生物学会年会、福岡、12月3日~6日、2019.
2018年度
第27回日本がん転移学会学術総会
1.太田みのり、玉井皓己、横山雄起、井上彬、畑泰司、松田宙、水島恒和、 土岐祐一郎、森正樹、山本浩文
大腸癌に対するICG光線力学療法 [一般口演]
第27回 日本がん転移学会学術集会・総会、横浜、7月19日~20日、2018.
2.石川翔、横山雄起、井上彬、三吉範克、高橋秀和、原口直紹、水島恒和、 土岐祐一郎、森正樹、山本浩文
KRAS変異型大腸癌に対するmiR-29b-1-5pの抗腫瘍効果の検討 [シンポジウム]
第27回 日本がん転移学会学術集会・総会、横浜、7月19日~20日、2018.
3.大石和樹、波多豪、横山雄起、原口直紹、畑泰司、松田宙、水島恒和、 土岐祐一郎、森正樹、山本浩文
大腸癌肝転移で発現低下を示すmiR-487bの役割 [ポスター]
第27回 日本がん転移学会学術集会・総会、横浜、7月19日~20日、2018.
第77回日本癌学会学術総会
1.森誠司、山本浩文、松浦成昭、高田義一
接着分子インテグリンと増殖因子の相互作用が癌進展において果たす役割 [シンポジウム]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
2.銭雅敏、呉しん、横山雄起、田口真衣、王かき、廣瀬遥香、森誠司、松浦成昭、山本浩文
E-cad-Fcコーティングによる癌幹細胞性質の増強 [口演 英語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
3.皆巳和賢、小泉雅彦、横山雄起、山本浩文、小川和彦
乳がん細胞において骨細胞によるSnail抑制作用はDrd2抑制剤の効果を抑制させる [口演 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
4. 山本浩文、森正樹
EPRを促進するsCAの中につめない利用法 [シンポジウム]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
5.安田知世、横山雄起、山本浩文
シグナル抑制性核酸投与時のReporter Assay法の検討 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
6.中根和昭、横山雄起、松浦成昭、山本浩文
ホモロジーの概念を用いた大腸癌興味領域抽出技術について [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
7.野村雅俊、原口直紹、三宅祐一朗、横山雄起、高橋秀和、三吉範克、西田尚弘、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
大腸癌血中循環細胞のsingle cell遺伝子解析 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
8.玉井皓己、井上彬、太田みのり、横山雄起、三吉範克、原口直紹、高橋秀和、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
スーパー炭酸アパタイトを用いた低侵襲ICG光線力学療法 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
9.武田昂樹、畑泰司、廣瀬遥香、三吉範克、高橋秀和、原口直紹、西田尚弘、松田宙、水島恒和、土岐祐一郎、
森正樹、山本浩文
Sox2遺伝子は大腸癌細胞に癌幹細胞様性質を賦与する [口演 英語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
10.大木明子、横山雄起、呉しん、井上彬、武田力、森正樹、村瀬研也、山本浩文
酸化鉄ナノ粒子含有製剤を用いた温熱療法による腫瘍抑制 [口演 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
11.池嶋遼、横山雄起、廣瀬遥香、高橋秀和、原口直紹、三吉範克、西田尚弘、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
ODCデグロン陽性細胞濃縮による静止期大腸癌幹細胞モデルの作製 [口演 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
12.辻村直人、横山雄起、井上彬、廣瀬遥香、三吉範克、高橋秀和、原口直紹、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
MicroRNA-29はDSS腸炎を抑制することにより発癌を抑える可能性がある [口演 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
13.外山愛、武田昂樹、横山雄起、磯賢治、波多豪、原口直紹、西田尚弘、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
大腸癌におけるp53とMAF蛋白の免疫染色学的検討 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
14.田口真衣、銭雅敏、呉しん、王かき、横山雄起、山本浩文
E-cad-Fcマトリックスは大腸癌細胞に上皮間葉転換を誘導する [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
15.五島碧、森誠司、横山雄起 、松浦成昭、山本浩文
FGF2とインテグリンの結合は乳癌の浸潤能を亢進させる [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
16.森本祥悠、井上彬、池嶋遼、横山雄起、高橋秀和、三吉範克、原口直紹、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
DCLK1をターゲットとした大腸癌に対する新規核酸治療の開発 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
17.柴田理志、横山雄起、山本浩文
ARHGEF10はRab8aの局在制御により細胞浸潤に関与している [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
18.久保田結衣、吉岡靖雄、横山雄起、呉しん、武田力、山本浩文
PD-L1 siRNAによる核酸治療の可能性 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
19.石川翔、高橋秀和、横山雄起、銭雅敏、廣瀬遥香、三吉範克、原口直紹、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
KRAS変異型大腸癌の核酸治療 [口演 英語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
20.宍戸明美、森誠司、横山雄起、濱田吉之輔、皆巳和賢、銭雅敏、王かき、廣瀬遥香、呉しん、河口直正、
南雲サチ子、松浦成昭、山本浩文
中皮細胞はスフェロイド中の卵巣癌細胞の幹細胞様形質を促進する [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
21.大石和樹、横山雄起、呉しん、水島恒和、土岐祐一郎、森正樹、山本浩文
大腸癌におけるLRP6蛋白の免疫組織化学的検討 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
22.呉しん、波多豪、横山雄起、大石和樹、三吉範克、原口直紹、高橋秀和、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
miR487bが大腸癌の転移を抑制する [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
23.横山雄起、武田和、北川公望、森誠司、水島恒和、森正樹、松浦成昭、山本浩文
BET阻害剤はALDH1A1遺伝子のスーパーエンハンサーを標的として卵巣癌のALDH活性を抑制する
[ポスター 英語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
24.武田和、横山雄起、北川公望、三吉範克、高橋秀和、原口直紹、西田尚弘、畑泰司、松田宙、水島恒和、
土岐祐一郎、森正樹、山本浩文
大腸癌細胞株におけるBET阻害剤JQ1の効果 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
25.廣瀬遥香、横山雄起、武田昂樹、池端克哉、池嶋遼、水島恒和、小泉雅彦、森正樹、山本浩文
プロモーター作動性癌細胞可視化システムの構築 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
26.太田みのり、松浦成昭、山本浩文
大腸癌リンパ節転移の分子診断 [ポスター 日本語]
第77回 日本癌学会学術総会、大阪、9月27日~29日、2018.
第41回日本分子生物学会年会
五島碧、森誠司、横山雄起、松浦成昭、山本浩文
FGF２とインテグリンの相互作用が乳癌細胞の浸潤転移に及ぼす影響 [ポスター]
第41回 日本分子生物学会年会、横浜、11月28日~30日、2018.